Document:

EX-4.14

 Exhibit 4.14 

**** INDICATES CONFIDENTIAL MATERIAL OMITTED PURSUANT TO A 

REQUEST FOR CONFIDENTIAL TREATMENT AND FILED WITH THE 

SECURITIES AND EXCHANGE COMMISSION SEPARATELY WITH A REQUEST 

FOR CONFIDENTIAL TREATMENT. 
  

			
	 Release version 2.1
 December 2016

 
	  	
		  	  
 Participants Agreement

 
 Cooperative Research Centre Project

 
  

		  	 Targeting Tropomyosin as a Novel Anti-Cancer Therapy

 

		  	  
 Parties

 
 Novogen Limited

 
 University of New South Wales

 
 ICP - Firefly Pty. Limited

 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 1	 

 Table of Contents 
  

									
	 1.
	  	 Definitionsand interpretation
	  	 	7	 
				
		  	1.1	  	Definitions	  	 	7	 
				
		  	1.2	  	Interpretation	  	 	10	 
				
		  	1.3	  	Priority of Agreement	  	 	11	 
			
	 2.
	  	Participant Contributions and Expectations	  	 	11	 
			
	 3.
	  	Participant Obligations	  	 	11	 
				
		  	3.1	  	General obligations	  	 	11	 
				
		  	3.2	  	Specific Obligations	  	 	12	 
				
		  	3.3	  	Work Orders	  	 	12	 
				
		  	3.4	  	Subcontract	  	 	13	 
				
		  	3.5	  	Specified Personnel	  	 	13	 
				
		  	3.6	  	Warranties	  	 	14	 
				
		  	3.7	  	Other government funding	  	 	14	 
				
		  	3.8	  	Relationship	  	 	14	 
				
		  	3.9	  	Acknowledgement of support	  	 	14	 
				
		  	3.10	  	In the event the Participant is unable to meet obligations	  	 	15	 
				
		  	3.11	  	Breach of the Participants Agreement	  	 	15	 
			
	 4.
	  	Intellectual Property Rights	  	 	15	 
				
		  	4.1	  	Intellectual Property	  	 	15	 
				
		  	4.2	  	Students engaged in the Project	  	 	16	 
				
		  	4.3	  	Moral Rights	  	 	16	 
				
		  	4.4	  	Use of Name and Trademarks	  	 	17	 
			
	 5.
	  	Participant Contributions and use of funds	  	 	17	 
				
		  	5.1	  	Project Partner Contributions	  	 	17	 
				
		  	5.2	  	Lead Participant	  	 	17	 
				
		  	5.3	  	Payments to UNSW	  	 	18	 
				
		  	5.4	  	Payments to ICP Firefly	  	 	18	 
				
		  	5.5	  	Separate Project financial accounts	  	 	19	 
				
		  	5.6	  	What CRC-P Funds can be used for	  	 	19	 
				
		  	5.7	  	What Funds cannot be used for	  	 	19	 
				
		  	5.8	  	When CRC-P Funds cannot be used	  	 	20	 
			
	 6.
	  	Repayment	  	 	20	 
				
		  	6.1	  	Misspent funds	  	 	20	 
				
		  	6.2	  	At the end of the Agreement Period	  	 	20	 
				
		  	6.3	  	Repayment Notice	  	 	20	 
				
		  	6.4	  	UNSW Reconciliation	  	 	20	 
			
	 7.
	  	GST and R&D Tax Incentive	  	 	21	 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 2	 

							
		  	7.1	  	Construction	  	21
				
		  	7.2	  	Consideration GST exclusive	  	21
				
		  	7.3	  	Payment of GST	  	21
				
		  	7.4	  	R&D Tax Incentive	  	21
			
	8.	  	Confidentiality	  	21
				
		  	8.1	  	Prohibition on disclosure	  	21
				
		  	8.2	  	Advisers and third parties	  	21
				
		  	8.3	  	Exceptions to obligations	  	22
				
		  	8.4	  	Obligation on disclosure	  	22
				
		  	8.5	  	Additional confidential information	  	22
				
		  	8.6	  	Confidential Information in Agreement Material	  	22
				
		  	8.7	  	Period of confidentiality	  	23
				
		  	8.8	  	No reduction in privacy obligations	  	23
				
		  	8.9	  	Return of information	  	23
			
	9.	  	Publication policy	  	23
			
	10.	  	Protection of personal information	  	25
				
		  	10.1	  	Definitions	  	25
				
		  	10.2	  	Application of this clause	  	25
				
		  	10.3	  	Personal Information other than Commonwealth provided Personal Information	  	25
			
	11.	  	Insurance	  	25
				
		  	11.1	  	Obligation to maintain insurance	  	25
				
		  	11.2	  	Certificates of Currency	  	26
				
		  	11.3	  	Self-Insurance or other protection	  	26
			
	12.	  	Work health and safety	  	26
			
	13.	  	Conflict of Interest	  	26
				
		  	13.1	  	Warranty	  	26
				
		  	13.2	  	Notification of a conflict of interest	  	26
			
	14.	  	Books and records	  	27
				
		  	14.1	  	Participant to keep books and records	  	27
				
		  	14.2	  	Reports	  	27
				
		  	14.3	  	Costs	  	27
			
	15.	  	Monitoring progress	  	27
			
	16.	  	Participants audit and access	  	28
			
	17.	  	Commonwealth audit and access	  	28
				
		  	17.1	  	Right to conduct audits	  	28
				
		  	17.2	  	Access by the Commonwealth	  	28
				
		  	17.3	  	Auditor-General and the Australian Information Commissioner	  	29
				
		  	17.4	  	Participants to comply with Auditor-General’s requirements	  	29
				
		  	17.5	  	No reduction in responsibility	  	29

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 3	 

							
		  	17.6	  	Subcontractor requirements	  	29
				
		  	17.7	  	No restriction	  	29
				
		  	17.8	  	Costs	  	29
			
	18.	  	False or misleading information	  	30
			
	19.	  	Safe and Ethical Research	  	30
			
	20.	  	Responsible conduct of research	  	30
			
	21.	  	Survival	  	31
			
	22.	  	Changes to the Agreement	  	31
			
	23.	  	Relationship to the Funding Agreement	  	31
			
	24.	  	Agreement Period and Termination	  	32
				
		  	24.1	  	Agreement Period	  	32
				
		  	24.2	  	Change of Project Partner	  	32
				
		  	24.3	  	Withdrawal of a Project Partner from the Agreement	  	33
				
		  	24.4	  	Consequences of removal of a Project Partner	  	34
				
		  	24.5	  	Termination of this Agreement for default	  	35
				
		  	24.6	  	Termination by Notice	  	35
				
		  	24.7	  	Suspension	  	35
				
		  	24.8	  	Consequences of termination– Intellectual Property	  	35
				
		  	24.9	  	Other consequences of termination	  	35
			
	25.	  	Liability and Indemnity	  	35
				
		  	25.1	  	Indemnity	  	35
				
		  	25.2	  	Consequential loss	  	36
				
		  	25.3	  	Maximum liability	  	36
			
	26.	  	Dispute resolution	  	36
				
		  	26.1	  	No arbitration or court proceedings	  	36
				
		  	26.2	  	Notification	  	36
				
		  	26.3	  	Parties to resolve Dispute	  	36
				
		  	26.4	  	Appointment of mediator	  	36
				
		  	26.5	  	Role of mediator and obligations of parties	  	37
				
		  	26.6	  	Confidentiality	  	37
				
		  	26.7	  	Costs	  	37
				
		  	26.8	  	Termination of process	  	37
			
	27.	  	Notices and other communications	  	37
				
		  	27.1	  	Service of Notices	  	37
				
		  	27.2	  	Effective on receipt	  	37
			
	28.	  	Miscellaneous	  	38
				
		  	28.1	  	No security	  	38
				
		  	28.2	  	Nature of obligations	  	38
				
		  	28.3	  	No adverse construction	  	38

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 4	 

									
		  	28.4	  	Approvals and consents	  	 	38	 
				
		  	28.5	  	Assignment and novation	  	 	38	 
				
		  	28.6	  	Costs	  	 	38	 
				
		  	28.7	  	Counterparts	  	 	38	 
				
		  	28.8	  	No merger	  	 	38	 
				
		  	28.9	  	Entire agreement	  	 	38	 
				
		  	28.10	  	Further action	  	 	38	 
				
		  	28.11	  	Severability	  	 	38	 
				
		  	28.12	  	Waiver	  	 	39	 
				
		  	28.13	  	Governing law and jurisdiction	  	 	39	 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 5	 

 Details 

 
  

			
	Date	  	15th     /     June     /     2017    
		  	day            month        year
		
	Parties	  	
		
	BETWEEN	  	Novogen Ltd (Lead Participant or Novogen)
		  	ABN: 37 063 259 754
		  	Suite 502, Level 5, 20 George St, Hornsby NSW 2077
		  	Email : Stephen.Palmer@novogen.com
		  	Attention : Dr Stephen Palmer
		
	AND	  	The University of New South Wales (UNSW)
		  	ABN: 57 195 873 179
		  	School of Medical Sciences, Wallace Wurth East, UNSW Australia, Kensington NSW 2052
		  	Email : p.gunning@unsw.edu.au
		  	Attention : Professor Peter Gunning
		
	AND	  	ICP - Firefly Pty. Limited (ICP Firefly)
		  	ABN: 66 071 626 358
		  	129 Queen Street, Beaconsfield NSW 2015
		  	Email : isabelle@icpfirefly.com.au
		  	Attention : Dr Isabelle Meyer-Carrive

 Background 
  

	A	The Parties have agreed to contribute to and participate in the Project. 

  

	B	Pursuant to the Funding Agreement with the Commonwealth, the CRC Project, Targeting Tropomyosin as a Novel Anti-Cancer Therapy, is funded through the Cooperative Research Centres (CRC) Programme. 

 

	C	This Agreement specifies the terms and conditions of the arrangements between the Parties and obliges them, as Participants, to make the Contributions and comply with other obligations as set out in this Agreement.

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 6	 

	1.	Definitions and interpretation 

  

	1.1	Definitions 

 In this Agreement, except where the contrary intention is expressed, the
following definitions are used: 
  

			
	Account	  	the bank account maintained by the Lead Participant with respect to the CRC-P Funds in accordance with clause 9.4 of the Funding Agreement.
		
	Accounting Standards	  	the accounting standards maintained by the Australian Accounting Standards Board (created by section 226 of the Australian Securities and Investments Commission Act 2001 (Cth)) or other accounting standards which are
generally accepted and consistently applied in Australia.
		
	Agreement	  	this agreement between the Participants, as varied from time to time in accordance with clause 22, and including its Schedules and any attachments.
		
	Agreement Material	  	any Material created on or following the commencement of the Funding Agreement, for the purpose of, or as a result of, a Participant undertaking and performing its obligations under the Project, including any improvements to any Pre-existing Materials.
		
	Agreement Period	  	the period from the Commencement Date to the End Date
		
	Asset	  	any item of tangible property purchased, leased, created or otherwise brought into existence either wholly or in part with use of the Funds, but does not include Agreement Material.
		
	Budget	  	the budget in part 2 of Schedule 3
		
	Business Day	  	a day that is not a Saturday, Sunday, public holiday or bank holiday in the place where the act is to be performed or where a Notice is received.
		
	Commencement Date	  	5 May 2017, or the date of execution of this Agreement, whichever is the later.
		
	Commonwealth	  	the Commonwealth of Australia.
		
	Confidential Information	  	 information that is by its nature confidential and:
  

(a)    is designated by a Party as confidential; or

 
 (b)    a Party knows or ought
to know is confidential; or
  

(c)    is described in item 6 of Schedule 1,

 
 but does not include:

 
 (d)    information that is or
becomes public knowledge otherwise than by breach of this Agreement or any other confidentiality obligation.

		
	Contribution	  	the cash, personnel, facilities and services to be provided by the Participants to the CRC-P, from their own resources, for the purposes of undertaking the Project, as specified in Schedule
3.

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 7	 

			
	CRC Indicia	  	the terms “CRC”, “CRC Projects”, “CRC-P”, “Cooperative Research Centre” and the CRC Programme logo and any additional items specified by the
Commonwealth from time to time.
		
	CRC Programme	  	the Cooperative Research Centres Programme.
		
	CRC Project (CRC-P)	  	the collaboration between the Participants for the purposes of undertaking the Project.
		
	CRC-P Funds	  	the Funds and any cash Contributions provided by the Participants for the purpose of the Project.
		
	End Date	  	the date on which this Agreement terminates or expires.
		
	Expected Funding	  	$1,500,000 over the course of the Agreement Period.
		
	Financial Year	  	the Australian financial year beginning 1 July and ending 30 June.
		
	Funds	  	the amounts payable by the Commonwealth to the Lead Participant under the Funding Agreement and any interest earned on those amounts.
		
	Funding Agreement	  	the funding agreement between the Commonwealth and the Lead Participant for the purposes of funding and managing the Project.
		
	Guidelines	  	the Programme Guidelines listed under item 2 of Schedule 1, and any other guidelines issued by the Commonwealth from time to time in relation to the CRC Programme and its administration.
		
	GST Law	  	A New Tax System (Goods and Services Tax) Act 1999(Cth).
		
	Intellectual Property Rights	  	 all intellectual property rights, including:
  

a)      copyright, patents, trademarks (including goodwill in those marks), designs,
trade secrets, know how, rights in circuit layouts, domain names and any right to have confidential information kept confidential;
  

b)      any application or right to apply for registration of any of the rights referred
to in paragraph (a); and
  

c)      all rights of a similar nature to any of the rights in paragraphs (a) and
(b) which may subsist in Australia or elsewhere,
  
 whether or not such rights are
registered or capable of being registered.

		
	ICP Firefly Services	  	the services as described in column 1 of Part C of Schedule 4.
		
	Law	  	any applicable statute, regulation, by-law, ordinance or subordinate legislation in force from time to time in Australia, whether made by a State, Territory, the Commonwealth, or a local
government, and includes the common law and rules of equity as applicable from time to time.
		
	Lead Participant	  	Novogen Limited ABN: 37 063 259 754.
		
	Lead Participant Services	  	the services as described in column 1 of Part A of Schedule 4.

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 8	 

			
	Material	  	includes property, information, data, results, images, models, molecules, software, firmware, documented methodology or process, documentation or other material in whatever form, including any reports, specifications, business
rules or requirements, user manuals, user guides, operations manuals, training materials and instructions, and the subject matter of any category of Intellectual Property Rights.
		
	Milestone	  	a stage of completion of the Project as set out in Schedule 2.
		
	Moral Rights	  	the right of integrity of authorship (that is, not to have a work subjected to derogatory treatment), the right of attribution of authorship of a work, and the right not to have authorship of a work falsely attributed, as defined
in the Copyright Act 1968 (Cth).
		
	Notice	  	a notice, demand, consent, approval or communication issued under this Agreement.
		
	Novogen Material	  	all Agreement Material other than the Technical Assay Material.
		
	Outcomes	  	the outcomes of the Project, as set out in Schedule 2.
		
	Participant	  	a person, body or organisation that is a signatory to this Agreement.
		
	Parties	  	the parties to this Agreement.
		
	Personnel	  	 (a)    in relation to a party, any employee, officer, agent, professional
adviser or subcontractor of that party; and
  

(b)    in relation to UNSW, includes the personnel identified in paragraph (a) of this
definition and any Students

		
	Pre-existing Material	  	Material owned by a party independently of this Agreement, including any Material specified in item 3 of Schedule 1.
		
	Project	  	the project set out in Schedule 2.
		
	Project Partner	  	all Participants other than the Lead Participant.
		
	Publication	  	any form of recorded medium that makes Agreement Material public, including print, images, video or audio, and ‘Publish’ has a corresponding meaning.
		
	Quarter	  	a period of 3 months or, where the context necessitates part or multiples of that period, ending on 31 March, 30 June, 30 September or 31 December.
		
	Related Entity	  	has the meaning given to that term in the Corporations Act 2001 (Cth).
		
	R&D Tax Incentive	  	is established by Division 355 of the Income Tax Assessment Act 1997 (Cth) with functions relating to its administration included in the Industry Research and Development Act 1986 (Cth).
		
	Shortfall	  	any deficit in the total Contributions received by the Lead Participant during a Financial Year and the Contributions which should have been received by the Lead Participant during that Financial Year as specified in Schedule
3.

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 9	 

			
	Specified Personnel	  	the Personnel (if any) specified in item 7 of Schedule 1.
		
	Student	  	any postgraduate or graduate student involved in the Project research.
		
	Technical Assay Material	  	 Agreement Material which is a technical assay and:
  

(a)    has been developed as part of the Project, with the purpose of testing the properties of
new chemical entities in biological systems; and
  

(b)    is not required in order for the Lead Participant to pursue Utilisation of any other
Agreement Material.

		
	Third Party Material	  	 Material owned by a third party that is:
  

(a)    included, embodied in or attached to the Agreement Material; or

 
 (b)    used in undertaking
the Project,
  
 as specified in item 4 of Schedule 1.

		
	UNSW Services	  	the services as described in column 1 of Part B of Schedule 4.
		
	UNSW Paid Amount	  	$300,000.
		
	UNSW Committed Amount	  	 (a)    if CRC-P Funds received by
UNSW during the Agreement Period meet or exceed $1,000,000, an amount which is equal to 20% of the value of the CRC-P Funds received; or
  

(b)    if CRC-P Funds received by UNSW during the
Agreement Period are less than $1,000,000, nil.

		
	Utilisation	  	technology transfer, take-up and use of research outputs by end-users. Commercial utilisation includes the manufacture, sale, hire or other
exploitation of a product or process, or the provision of a service, incorporating Agreement Material or licensing of any third party to do any of those things, or otherwise licensing or assigning the Agreement Material.
		
	WHS Laws	  	the Work Health and Safety Act 2011 (Cth), regulations made under that Act and any code of practice approved for the purpose of that Act.
		
	Work Order	  	an agreement to provide services to the CRC-P in accordance with clause 3.3.

  

	1.2	Interpretation 

 In this Agreement, except where the contrary intention is expressed:

  

	 	(a)	the singular includes the plural and vice versa, and a gender includes other genders; 

  

	 	(b)	another grammatical form of a defined word or expression has a corresponding meaning; 

  

	 	(c)	a reference to a clause, paragraph or schedule is to a clause or paragraph of, or schedule to, this Agreement; 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 10	 

	 	(d)	a reference to a document or instrument includes the document or instrument as novated, altered, supplemented or replaced from time to time; 

 

	 	(e)	a reference to A$, $A, dollar or $ is to Australian currency; 

  

	 	(f)	a reference to time is to Canberra, Australia time; 

  

	 	(g)	a reference to a party to a document includes the party’s executors, administrators, successors and permitted assignees and substitutes; 

 

	 	(h)	a reference to a person includes a natural person, partnership, body corporate, association, governmental or local authority or agency or other entity; 

 

	 	(i)	a reference to a statute, ordinance, code or other law includes regulations and other instruments under it and consolidations, amendments, re-enactments or replacements of any of
them; 

  

	 	(j)	the meaning of general words is not limited by specific examples introduced by including, for example or similar expressions, and the words “includes” or “including” shall be read as being followed
by “without limitation”; 

  

	 	(k)	any agreement, representation, warranty or indemnity by two or more parties (including where two or more persons are included in the same defined term) binds each of them severally and does not bind them jointly;

  

	 	(l)	any agreement, representation, warranty or indemnity in favour of two or more parties (including where two or more persons are included in the same defined term) is for the benefit of them jointly and severally;

  

	 	(m)	a rule of construction does not apply to the disadvantage of a party because the party was responsible for the preparation of this Agreement or any part of it; 

 

	 	(n)	if a day on or by which an obligation must be performed or an event must occur is not a Business Day, the obligation must be performed or the event must occur on or by the next Business Day; and 

 

	 	(o)	headings are for ease of reference only and do not affect interpretation. 

  

	1.3	Priority of Agreement 

 To the extent of any inconsistency the body of this Agreement and
the Schedules, the body of this Agreement will prevail. 
  

	2.	Participant Contributions and Expectations 

  

	 	(a)	During the Agreement Period, the Participants will make the Contributions to the CRC-P as detailed in Schedule 3. 

 

	 	(b)	During the Agreement Period, the Participants will provide the products, services and/or access for the purposes of the Project as outlined in item 4 of Schedule 2 and as well as the specific services set out in
Schedule 4. 

  

	 	(c)	UNSW will not charge any indirect on-costs to the Lead Participant for any direct or in-kind expenses related to the CRC-P or the Project. 

  

	3.	Participant Obligations 

  

	3.1	General obligations 

 Each Participant agrees that it will: 

 

	 	(a)	diligently perform its obligations as set out in this Agreement to a high professional standard; 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 11	 

	 	(b)	undertake the Project to achieve the Outcomes, at the times and in the manner specified in Schedule 2 of this Agreement; 

  

	 	(c)	make its Contributions to the CRC-P, through the Lead Participant, in accordance with Schedule 3 and any other requirements under this Agreement; 

 

	 	(d)	meet the due dates for the Milestones, as specified in Schedule 2; 

  

	 	(e)	undertake the Project in accordance with the Guidelines; 

  

	 	(f)	cooperate with, and provide to, the Lead Participant any information about the Contributions, any anticipated Shortfall and other activities reasonably required by the Lead Participant; 

 

	 	(g)	keep the CRC-P informed through the Lead Participant about the results of the Project and any other information relevant to the conduct of the Project in which the Participant is
involved, including through the submission of Quarterly update reports; 

  

	 	(h)	support the Lead Participant to meet its obligations to the Commonwealth under the Funding Agreement; 

  

	 	(i)	support the CRC-P in meeting its obligations in compliance with law and policy, and comply with the provisions of any relevant statutes, regulations, by-laws, and requirements of any Commonwealth, State, Territory or local authority; and 

  

	 	(j)	act reasonably and in good faith with the other Participants. 

  

	3.2	Specific Obligations 

  

	 	(a)	The Lead Participant must provide the Lead Participant Services to the CRC-P in accordance with: 

 

	 	(i)	any applicable service standards described in column 2 of Part A of Schedule 4; and 

  

	 	(ii)	all applicable Laws. 

  

	 	(b)	UNSW must provide the UNSW Services to the CRC-P in accordance with: 

  

	 	(i)	any applicable service standards described in column 2 of Part B of Schedule 4; and 

  

	 	(ii)	all applicable Laws. 

  

	 	(c)	ICP Firefly must provide the ICP Firefly Services to the CRC-P in accordance with: 

  

	 	(i)	any applicable service standards described in column 2 of Part C of Schedule 4; and 

  

	 	(ii)	all applicable Laws. 

  

	 	(d)	The Participants may vary the services specified in Schedule 4 from time to time by agreement in writing. 

  

	3.3	Work Orders 

  

	 	(a)	During the Agreement Period, the Lead Participant may submit a Work Order to a Project Partner with respect to reasonable specific services to be provided to the CRC-P in addition
to those outlined in Schedule 4. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 12	 

	 	(b)	If the Lead Participant requests that a Project Partner provides a quote for services to be conducted under a Work Order prior to submitting a Work Order under clause 3.3(a), the Project Partner must, acting reasonably
and in good faith, prepare and provide an itemised quote to the Lead Participant within 10 Business Days of such request. 

  

	 	(c)	Each Work Order must be within the scope of the Project, and must comply with the Budget and Contributions relevant to the Project Partner. 

 

	 	(d)	A Project Partner will be deemed to have accepted a Work Order unless the Project Partner has given Notice to the Lead Participant within 5 Business Days of receipt of the Work Order that it cannot reasonably provide
the services described in the Work Order. 

  

	 	(e)	Each accepted Work Order will set out the full details of the services to be provided, any applicable service standards and any other relevant information and instructions. 

 

	3.4	Subcontract 

  

	 	(a)	The Project Partners must not sub-contract any of their obligations under this Agreement without the prior written permission of the Lead Participant. 

 

	 	(b)	Any sub-contracting by a Project Partner of an obligation under this Agreement: 

  

	 	(i)	must be on broadly the same terms as this Agreement; 

  

	 	(ii)	must include terms which meet the requirements of clause 13 of the Funding Agreement as if the Project Partner was the Lead Participant; and 

 

	 	(iii)	does not relieve a Project Partner of any of its liabilities or obligations under this Agreement. 

  

	 	(c)	The Project Partner is liable to the Lead Participant for the acts, defaults and omissions of the sub-contractor, or any of the
sub-contractor’s Personnel, as if they were the acts, defaults or omissions of the Project Partner. 

  

	3.5	Specified Personnel 

  

	 	(a)	Each Participant must: 

  

	 	(i)	undertake the Project or any part of the Project to which their particular expertise relates, with the active involvement of, and using the expertise of, its Specified Personnel or any persons who are appointed to
replace them in accordance with the requirements under clause 3.5(c); and 

  

	 	(ii)	ensure that each of its Specified Personnel is aware of and complies with the Participant’s obligations in undertaking the Project. 

 

	 	(b)	Where one or more of the Specified Personnel is or will become unable or unwilling to be involved in the Project, the relevant Participant must notify the Lead Participant in writing immediately of any change to the
Specified Personnel. 

  

	 	(c)	When replacing Specified Personnel, the Participants must ensure that any such replacement personnel directly involved in the Project has the time commitment, qualifications and competency to undertake the Project to
the standard required by the Agreement and have similar or better suited expertise and ability to those of the Personnel they are replacing. 

  

	 	(d)	The Commonwealth may at any time request to remove from work in respect of this Agreement any of the Specified Personnel or any of a Participant’s subcontractors or Personnel. If a request is made, the relevant
Participant must promptly arrange for the removal of such subcontractors or Personnel, and arrange for a replacement in accordance with the requirements under clause 3.5(c). 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 13	 

	3.6	Warranties 

 Each Participant represents and warrants that: 

 

	 	(a)	it has the right to enter into this Agreement; 

  

	 	(b)	it and its subcontractors and Personnel, including its Specified Personnel, have the necessary experience, skill, knowledge, expertise and competence to undertake the Project and (where appropriate) will hold such
licences, permits or registrations as are required under any State, Territory or Commonwealth legislation to undertake the Project, and are fit and proper people. 

 

	3.7	Other government funding 

  

	 	(a)	Each Participant must provide to the Lead Participant full details of any financial assistance for activities in connection with the Project which the Participant receives from another Commonwealth, State or Territory
government source or agency after the commencement of this Agreement (Other Financial Assistance), including: 

  

	 	(i)	the amount and source of the funding; and 

  

	 	(ii)	the name of the programme under which it was provided, 

 within 10 Business Days of the
Participant receiving notice that the Other Financial Assistance has been approved. 
  

	 	(b)	The parties acknowledge that the: 

  

	 	(i)	Commonwealth may reduce, suspend or defer its payments in the event a Participant receives Other Financial Assistance, but only to the extent that this financial assistance duplicates Funds; and 

 

	 	(ii)	any reduction in Funds received will result in a corresponding reduction of funding provided under this Agreement. 

  

	3.8	Relationship 

  

	 	(a)	Each Party must not present itself, and ensure its officers, employees, agents and other Personnel do not represent themselves, as being an officer, employee, partner, agent or other Personnel of the Commonwealth or
another Participant, or as otherwise able to bind or represent the Commonwealth or another Participant. 

  

	 	(b)	This Agreement does not create a relationship of employment or agency, joint venture, partnership, or of trustee and beneficiary between the Parties. 

 

	3.9	Acknowledgement of support 

 Each Participant must, in: 

 

	 	(a)	all of its publications (including reprints and despite whether published by the Participant or other persons) that are a result of the Project; 

 

	 	(b)	any of its products, processes or inventions produced as a direct result of the Project activities; and 

  

	 	(c)	all of its promotional and advertising materials, public announcements, events and activities in relation to the Project; 

acknowledge the financial and other support received from the Commonwealth: 

 

	 	(d)	through reference to this support and the CRC Programme; 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 14	 

	 	(e)	in relation to clause 3.9(c), through prominent display of the CRC Indicia; and 

  

	 	(f)	by reference to any acknowledgement as otherwise specified by the Commonwealth from time to time. 

  

	3.10	In the event the Participant is unable to meet obligations 

 Each Participant must notify
the Lead Participant and all Project Partners immediately upon becoming aware of any circumstances that are likely to adversely affect the Participant’s ability to comply with the terms of this Agreement, in particular its solvency or ability
to ensure that the Project is carried out in accordance with this Agreement. This includes notification of any intent of, or changes in circumstances leading to the need for, withdrawal from the CRC-P and the
Project. The giving of Notice pursuant to this clause 3.10 will not, in any way, limit the obligations of the Participant under this Agreement or excuse the Participant in any way from the performance of those obligations. 

 

	3.11	Breach of the Participants Agreement 

 Each Participant must, within 5 Business Days of
becoming aware of any breach or suspected breach of this Agreement that would affect the Lead Participant’s ability to comply with its obligations under the Funding Agreement: 

 

	 	(a)	provide Notice to the Lead Participant and all Project Partners of that breach or suspected breach; 

  

	 	(b)	provide all information reasonably required by the Lead Participant in relation to the breach or suspected breach; 

  

	 	(c)	identify to the Lead Participant and all Project Partners the steps the Participant intends to take to address the matter; 

  

	 	(d)	keep the Lead Participant and all Project Partners informed of any action it takes to remedy the breach; and 

  

	 	(e)	provide Notice to the Lead Participant and all Project Partners once the breach is remedied, or if not remedied upon the matter being otherwise resolved. 

 

	4.	Intellectual Property Rights 

  

	4.1	Intellectual Property 

  

	 	(a)	This clause 4 does not affect the ownership of the Intellectual Property Rights in any Pre-existing Material or Third Party Material. 

 

	 	(b)	The Project Partners must obtain all necessary copyright and other Intellectual Property Rights permissions before making any Third Party Material available for the purpose of this Agreement or the Project.

  

	 	(c)	The Project Partners must specify which parts (if any) of the Intellectual Property Rights are Third Party Material and who owns the Intellectual Property Rights in that material. 

 

	 	(d)	The Intellectual Property Rights in the Agreement Material will vest in the Participants on creation as agreed in Schedule 5. 

  

	 	(e)	Each Participant will adhere to the documented arrangements and procedures for dealing with Intellectual Property Rights in Agreement Material as set out in Schedule 5. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 15	 

	 	(f)	Each Participant will adhere to the documented arrangements and procedures, as set out in clause 9 to ensure that, prior to the publication or disclosure of Agreement Material (but not including reports or other such
material to be provided to the Commonwealth for the Commonwealth’s benefit), consideration is given to the potential prejudice to its subsistence or Utilisation, including the possibility that publication or disclosure might preclude the grant
of a patent or cause the loss of Intellectual Property Rights. 

  

	 	(g)	Each Participant must ensure that any Utilisation of Agreement Material in the context of this Agreement: 

  

	 	(i)	is consistent with the Milestones, the nature of the Project and the CRC Programme; and, 

  

	 	(ii)	maximises the national benefits accruing to Australia. 

  

	 	(h)	To the extent that the Commonwealth needs to use any of the Agreement Material in connection with the Funding Agreement or CRC Programme, including but not limited to: 

 

	 	(i)	the use of reports provided by the Lead Participant to the Commonwealth; or 

  

	 	(ii)	the exercise of the Commonwealth’s rights under clause 17 (Commonwealth Audit & Access); 

each Participant grants to, or must obtain for, the Commonwealth a perpetual, world-wide, royalty free,
non-exclusive licence (including the right to sublicense) to use, reproduce, adapt, modify and communicate that Material. 
  

	 	(i)	The licence granted to the Commonwealth under clause 4.1(h) does not include a right to exploit the Agreement Material for the Commonwealth’s commercial purposes. 

 

	4.2	Students engaged in the Project 

 The Participants acknowledge that UNSW has obligations
under its governing statues to ensure that Students completing a thesis are able to complete the requirements of their candidature and that this obligation extends to submitting a Student’s thesis for examination and depositing in the library a
copy of the Student’s complete thesis of work submitted for a higher degree. In accordance with this acknowledgment it is accepted that: 
  

	 	(a)	all Agreement Material created by the Student and all Intellectual Property Rights in such material (Student Material) will vest in the Participants as agreed in Schedule 5 on creation (except that the Student
owns copyright and Moral Rights in his/her thesis); 

  

	 	(b)	UNSW will procure that the Student assigns to the Participants all right, title and interest in the Student Material and agrees to do all things reasonably necessary to give effect to such ownership and assignment; and

  

	 	(c)	the Student is entitled to Publish the Student Material in accordance with clause 9 of this Agreement. 

  

	4.3	Moral Rights 

  

	 	(a)	To the extent permitted by applicable Laws and for the benefit of the Commonwealth and the Lead Participant, each Project Partner must use its best endeavours to ensure that: 

 

	 	(i)	each of the Personnel used by the Project Partner in the production or creation of the Agreement Material gives, in a form acceptable to the Lead Participant; and 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 16	 

	 	(ii)	any holder of Moral Rights in Third Party Material included in the Agreement Material gives, 

genuine consent in writing to the use of the Agreement Material for the Specified Acts, even if such use would otherwise be an infringement of
its or their Moral Rights and notify the Lead Participant if this consent is not obtained. 
  

	 	(b)	In this clause 4.3 Specified Acts means: 

  

	 	(i)	falsely attributing the authorship of any Agreement Material, or any content in the Agreement Material (including literary, dramatic, artistic works and cinematograph films within the meaning of the Copyright Act 1968
(Cth)); 

  

	 	(ii)	materially altering the style, format, colours, content or layout of the Agreement Material and dealing in any way with the altered Agreement Material; 

 

	 	(iii)	reproducing, communicating, adapting, publishing or exhibiting any Agreement Material; and 

  

	 	(iv)	adding any additional content or information to the Agreement Material. 

  

	4.4	Use of Name and Trademarks 

 Except as reasonably required to comply with Law, the
Funding Agreement or the rules of any financial market on which a Party or a Related Entity of a Party is listed, each Participant shall not use another Participant’s name or trademarks without the express permission of that party. 

 

	5.	Participant Contributions and use of funds 

  

	5.1	Project Partner Contributions 

  

	 	(a)	Each Project Partner shall pay its annual cash component of its Contributions into the Account within 30 days after the first day of each applicable Financial Year during the Agreement Period. 

 

	 	(b)	The Lead Participant shall send the Project Partner a tax invoice at least14 days before the end of each Financial Year during the Agreement period, for the cash amount due at the start of the next Financial Year. Each
annual payment by the Project Partner of its cash component shall be the Contribution due plus GST, if applicable. 

  

	 	(c)	The valuation of the non-cash-in-kind Contribution of a Project Partner shall be in accordance with
the Accounting Standards and any valuation principles provided by the Commonwealth from time to time, and reported to the Lead Participant on request. 

  

	5.2	Lead Participant 

  

	 	(a)	The Lead Participant shall pay its annual cash component of its Contributions into the Account within 30 days after the Commencement Date, or within 30 days after the first day of each applicable Financial Year during
the Agreement Period (whichever is applicable). 

  

	 	(b)	The Lead Participant shall pay the CRC-P Funds out of the Account to the Project Partners in accordance with the Budget, Schedule 3 and this clause 5. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 17	 

	5.3	Payments to UNSW 

  

	 	(a)	Subject to the remainder of this clause 5.3 the Lead Participant shall: 

  

	 	(i)	pay to UNSW the amount specified for Q3 in item 3 of Schedule 3 within 30 days of the Commencement Date; and 

  

	 	(ii)	make Quarterly payments of the CRC-P Funds due under item 3 of Schedule 3 to UNSW: 

  

	 	(A)	with respect to amounts from Contributions, within 30 days of the end of each Quarter during the Term; 

  

	 	(B)	with respect to amounts from the Funds, within 30 days of the receipt of the Funds from the Commonwealth. For the avoidance of doubt, the Lead Participant will not be required to pay any amount of the Funds to UNSW
unless and until such Funds have been received from the Commonwealth. 

  

	 	(b)	The Lead Participant may vary the amount specified in item 3 of Schedule 3 at any time during the Term, by giving written Notice to UNSW, provided that: 

 

	 	(i)	the Lead Participant will take into account the reasonable comments of UNSW in making any variations; and 

  

	 	(ii)	any variations must be in accordance with the Budget. 

  

	 	(c)	Any amount payable to UNSW under a Work Order will be as set out in that agreed Work Order. 

  

	 	(d)	UNSW must issue a valid tax invoice to the Lead Participant for the amount due under this clause 5.3, prior to the Lead Participant making any payment of CRC-P Funds in accordance
with this clause 5.3. 

  

	 	(e)	UNSW acknowledges and agrees that the Lead Participant is not liable for the provision of additional money to meet any expenditure in excess of the Funds or a Participant’s Contribution under the Budget, without
the written consent of the Lead Participant. 

  

	 	(f)	UNSW acknowledges and agrees that any amount specified in the Budget or due to be paid under a Work Order or this clause 5.3 will be reduced in proportion with any reduction in funding under the Funding Agreement. The
Lead Participant will seek to ensure that any such reduction will be in accordance with the aims of the Project. 

  

	5.4	Payments to ICP Firefly 

  

	 	(a)	Subject to clauses 5.4(b) and 5.4(c), and unless otherwise agreed by the Parties in writing, the Lead Participant will pay to ICP Firefly the amount as specified in each agreed Work Order as out of the CRC-P Funds as follows: 

  

	 	(i)	70% of the total cost of the Work Order within 30 days of the later of: 

  

	 	(A)	signature of the Work Order; and 

  

	 	(B)	the receipt by the Lead Participant of a validly issued tax invoice for the amount due; and 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 18	 

	 	(ii)	30% of the total cost of the Work Order within 30 days of the later of: 

  

	 	(A)	the receipt by the Lead Participant of a final report that meets the service standards laid out in Part C of Schedule 4; and 

  

	 	(B)	the receipt by the Lead Participant of a validly issued tax invoice for the amount due. 

  

	 	(b)	ICP Firefly acknowledges and agrees that the Lead Participant is not liable for the provision of additional money to meet any expenditure in excess of the Funds or a Participant’s Contribution under the Budget
without the written consent of the Lead Participant. 

  

	 	(c)	ICP Firefly acknowledges and agrees that: 

  

	 	(i)	any amount specified in a Work Order or due to be paid under this clause 5.4 will be reduced in proportion with any reduction in funding under the Funding Agreement; 

 

	 	(ii)	on request of the Lead Participant, ICP Firefly must immediately repay funds received under a Work Order to the extent that such funds correspond with a reduction in funding under the Funding Agreement.

 The Lead Participant will seek to ensure that any reduction of funding will be in accordance with the aims of the Project.

  

	5.5	Separate Project financial accounts 

 Each Participant must keep separate financial
accounts which must record: 
  

	 	(a)	any Contributions it makes; 

  

	 	(b)	any payments of CRC-P Funds made to it by the Lead Participant; 

  

	 	(c)	any payment made in relation to an Asset greater than $300; and 

  

	 	(d)	expenditure incurred by the Participant from CRC-P Funds in carrying out the Project. 

  

	5.6	What CRC-P Funds can be used for 

  

	 	(a)	The Participants must spend the CRC-P Funds only for the purposes of undertaking the Project. 

 

	 	(b)	The Participants must spend the CRC-P Funds only in accordance with the Budget. 

  

	 	(c)	Subject to clause 5.6(d), the Lead Participant may vary the Budget by re-allocating expenditure between heads of expenditure specified in the Budget. 

 

	 	(d)	Any variation under clause 5.6(c) which increases or decreases the amount allocated to a head of expenditure by more than 10% cannot be made without the Commonwealth’s prior written approval. 

 

	5.7	What Funds cannot be used for 

 The Participants must not spend the Funds: 

 

	 	(a)	for capital works or for the purchase or construction of facilities such as buildings or laboratories; 

  

	 	(b)	for renovation or extension of buildings and facilities unless approved by the Commonwealth in writing; 

  

	 	(c)	for any activities for which the Participants have previously been funded, or are currently being funded by the Commonwealth Government or a State or Territory government either directly or indirectly through any other
funding scheme; 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 19	 

	 	(d)	to reimburse a Participant for the costs associated with existing staff or other resources committed by the Participant to the Project as in-kind contributions under this
Agreement; 

  

	 	(e)	to pay a Participant for the indirect support costs of research in relation to cash-funded Project staff located in their organisation; or 

 

	 	(f)	for the indirect support costs of research conducted overseas. 

  

	5.8	When CRC-P Funds cannot be used 

  

	 	(a)	Without limiting any other right or remedy of the Lead Participant, the Lead Participant may by Notice direct a Participant not to spend CRC-P Funds if the Lead Participant
receives a notice from the Commonwealth under clause 9.3 of the Funding Agreement. 

  

	 	(b)	A Participant must not spend any CRC-P Funds after the Lead Participant issues Notice under clause 5.8(a) unless and until the Commonwealth notifies the Lead Participant otherwise
and the Lead Participant, in turn, notifies the Participant accordingly. 

  

	6.	Repayment 

  

	6.1	Misspent funds 

 The Lead Participant is entitled to recover from a Project Partner any
amount of money which has been spent by that Project Partner which: 
  

	 	(a)	in the Lead Participant’s opinion, was spent other than in accordance with this Agreement; or 

  

	 	(b)	the Commonwealth has recovered from the Lead Participant in accordance with clauses 15.3(h), 10.1 or 10.2 of the Funding Agreement. 

 

	6.2	At the end of the Agreement Period 

 After the end of this Agreement, the Lead
Participant is entitled to recover from the CRC-P Funds any funds which had been paid to a Project Partner in accordance with clause 5.2 and which have not been spent, or legally committed for expenditure by a
Project Partner in accordance with this Agreement and payable by the Participant as a current liability (written evidence of which will be required). 
  

	6.3	Repayment Notice 

  

	 	(a)	The Lead Participant may give a Project Partner a Notice requiring the Project Partner to repay to the Lead Participant (or deal with as specified by the Lead Participant) an amount which the Lead Participant is
entitled to recover under clause 6.1 and 6.2. 

  

	 	(b)	If the Lead Participant gives a Notice under clause 6.3(a), the Project Partner must repay the amount specified in the Notice in full (or deal with it as specified by the Lead Participant) within 30 days of the date of
the Notice. 

  

	6.4	UNSW Reconciliation 

  

	 	(a)	If, following the end of this Agreement for any reason other than breach of the Agreement by UNSW, UNSW has received less than the Expected Funding from the CRC-P Funds during the
Agreement Period, the Lead Participant will: 

  

	 	(i)	issue Notice to UNSW setting out the difference (if any) between the UNSW Paid Amount and the UNSW Committed Amount (Reconciliation Amount) within 30 days of the End Date; and 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 20	 

	 	(ii)	pay the Reconciliation Amount (if any) to UNSW within 30 days of the issue of the Notice in accordance with clause 6.4(a). 

  

	 	(b)	Any Reconciliation Amount paid by the Lead Participant to UNSW in accordance with this clause 6.4 must not be paid out of any CRC-P Funds. 

 

	7.	GST and R&D Tax Incentive 

  

	7.1	Construction 

 In this clause 7 words and expressions which are not defined in this
Agreement but which have a defined meaning in the GST Law have the same meaning as in the GST Law. 
  

	7.2	Consideration GST exclusive 

 Unless otherwise expressly stated, all prices or other sums
payable or consideration to be provided under this Agreement are exclusive of GST. 
  

	7.3	Payment of GST 

  

	 	(a)	If GST is payable by a supplier on any supply made under this Agreement, the recipient of the supply will pay to the supplier an amount equal to the GST payable on the supply, in addition to and at the same time that
the consideration for the supply is to be provided under this Agreement. 

  

	 	(b)	The Parties acknowledge that they are registered for GST and will notify the other Parties if they cease to be registered for GST. 

  

	7.4	R&D Tax Incentive 

 To assist certain Participants claim the R&D Tax Incentive,
the CRC-P must expend (or allocate) contributions from Participants on (or to) R&D activities, as defined under subdivision 355B section 355-20 of the Income Tax
Assessment Act 1997 (Cth) and maintain records of the date when such expenditure on which R&D activities occurred. 
  

	8.	Confidentiality 

  

	8.1	Prohibition on disclosure 

 Subject to clause 8.3, each Participant must not: 

 

	 	(a)	without the prior written consent of the relevant Participant, disclose that Participant’s Confidential Information to a third party or use such Confidential Information other than for the purpose of the Project;
and 

  

	 	(b)	without the prior written consent of the Commonwealth, disclose any Commonwealth Confidential Information obtained through Project-related activities to a third party or use such Confidential Information other than for
the purpose of the Project. 

  

	8.2	Advisers and third parties 

 The Participants agree that, following a request from the
Commonwealth, each Participant must provide the Lead Participant with a written undertaking from each Participant’s Personnel relating to the use and non-disclosure of the Commonwealth’s Confidential
Information in the form approved by the Commonwealth. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 21	 

	8.3	Exceptions to obligations 

 The obligations on each Party under clause 8.1 will not be
taken to have been breached to the extent that Confidential Information of the other Parties or Confidential Information of the Commonwealth: 
  

	 	(a)	is disclosed by a Party to its advisers or employees solely in order to comply with obligations, or to exercise rights, under this Agreement; 

 

	 	(b)	is disclosed to a Party’s internal management personnel, solely to enable effective management or auditing of activities related to this Agreement; 

 

	 	(c)	is required by Law or rules of a financial market on which a Party or a Related Entity of a Party is listed, to be disclosed; 

  

	 	(d)	is disclosed to the Commonwealth for the purposes of the Project, the CRC Programme or as otherwise provided for under the exceptions listed in clause 20.4 of the Funding Agreement; 

 

	 	(e)	is in the public domain otherwise than due to a breach of this Agreement; and 

  

	 	(f)	is independently received from a third party who is free to disclose it. 

  

	8.4	Obligation on disclosure 

 Where a Party discloses Confidential Information of a Party or
Confidential Information of the Commonwealth to another person, pursuant to clauses 8.3(a) or (b), the disclosing party must: 
  

	 	(a)	notify the receiving person that the information is Confidential Information; 

  

	 	(b)	not provide the information unless the receiving person agrees to keep the information confidential; and 

  

	 	(c)	including, in the case of Commonwealth Confidential Information, the receiving person must give the Commonwealth a legally binding undertaking to that effect in the form approved by the Commonwealth. 

 

	8.5	Additional confidential information 

  

	 	(a)	The Parties may agree in writing during the Agreement Period that certain additional information is to constitute Confidential Information for the purposes of this Agreement. 

 

	 	(b)	Where the Parties agree in writing during the Agreement Period that certain additional information is to constitute Confidential Information for the purposes of this Agreement, this documentation is incorporated into,
and becomes Confidential Information under this Agreement, on the date by which both Parties have signed this documentation. 

  

	8.6	Confidential Information in Agreement Material 

 For the avoidance of doubt, for the
purposes of this Agreement: 
  

	 	(a)	all Agreement Material, other than Technical Assay Material, will be the “Confidential Information” of the Lead Participant; 

 

	 	(b)	all Technical Assay Material will be the “Confidential Information” of UNSW; and 

  

	 	(c)	each Party may make use of its own Confidential Information as it sees fit and without restriction under this Agreement. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 22	 

	8.7	Period of confidentiality 

 The obligations under this clause 8 continue, notwithstanding
the expiry or termination of this Agreement: 
  

	 	(a)	in relation to an item of information described in item 6 of Schedule 1, for the period set out in that Schedule in respect of that item; and 

 

	 	(b)	in relation to any information which the Parties agree in writing after the date of this Agreement is to constitute Confidential Information for the purposes of this Agreement, for the period agreed by the Parties in
writing in respect of that information. If there is no agreement in writing with respect to period in which certain information is to constitute Confidential Information for the purposes of this Agreement it will be taken that that information is to
constitute Confidential Information in perpetuity until that information is made public other than through a breach of this Agreement or other confidentiality obligation. 

 

	8.8	No reduction in privacy obligations 

 The Participants agree that nothing in this
Agreement derogates from any obligation which any Party may have under the Privacy Act 1988 (Cth) as amended from time to time, in relation to the protection of ‘personal information’ as defined in that Act or information that is
protected by the Census and Statistics Act 1905 (Cth), or any other Law requiring secrecy or confidentiality in dealing with information. 
  

	8.9	Return of information 

  

	 	(a)	Subject to clause 8.9(c), the Participants agree that at the request of the Commonwealth or on the expiry or termination of the Funding Agreement, each Participant must promptly return all of the Commonwealth’s
physical and written records containing Confidential Information, and all documentation relating to that Confidential Information (including copies), to the Commonwealth in a form reasonably requested by the Commonwealth. Alternatively, the
Participants agree that if requested by the Commonwealth, each Participant must destroy such items in the manner specified by the Commonwealth and promptly certify to the Commonwealth in writing that it has done so. 

 

	 	(b)	Subject to clause 8.9(c), at the request of a Participant or on the expiry or termination of this Agreement, each other Participant must promptly return all of the requesting Participant’s Confidential Information,
and all documentation relating to that Confidential Information (including copies). 

  

	 	(c)	A Participant may retain copies of Confidential Information: 

  

	 	(i)	required to comply with Law or the rules of any financial market on which a Participant, or a Related Entity of the Participant, is listed; and/or 

 

	 	(ii)	included in any accounts, notices, agendas, submissions, memoranda, board papers and minutes for the board of the Participant. 

  

	9.	Publication policy 

  

	 	(a)	All Participants recognise and support the desire to Publish and disclose aspects of the Agreement Material that advance scientific knowledge in journals or public meeting presentations. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 23	 

	 	(b)	In order for a Project Partner or its Personnel to Publish Novogen Material for any purpose other than reports to the Commonwealth under the Funding Agreement it is accepted that: 

 

	 	(i)	the applicant seeking to Publish will submit the proposed disclosure documents to the Lead Participant at least 30 days before the proposed disclosure date; 

 

	 	(ii)	the Lead Participant will complete its review of the disclosure within the 30-day review period; and 

 

	 	(iii)	if, during the review period, the Lead Participant notifies the applicant that: 

  

	 	(A)	it aims to file patent applications on any inventions disclosed in the documents or register any other intellectual property protections, then the applicant will defer disclosure for up to a total of 90 days from such
Notice being received from the Lead Participant; and 

  

	 	(B)	the Publication includes any reference to the Lead Participant’s Confidential Information, then subject to clause 9(d), the applicant party must remove such Confidential Information from the Publication prior
to Publishing the relevant work. 

  

	 	(c)	In order for a Lead Participant or ICP Firefly or its Personnel to Publish Technical Assay Material for any purpose other than reports to the Commonwealth under the Funding Agreement it is accepted that:

  

	 	(i)	the applicant seeking to Publish will submit the proposed disclosure documents to UNSW at least 30 days before the proposed disclosure date; 

 

	 	(ii)	UNSW will complete its review of the disclosure within the 30-day review period; and 

  

	 	(iii)	If, during the review period, UNSW notifies the applicant that: 

  

	 	(A)	it aims to file patent applications on any inventions disclosed in the documents or register any other intellectual property protections, then the applicant will defer disclosure for up to a total of 90 days from such
Notice being received from UNSW; and 

  

	 	(B)	the Publication includes any reference to UNSW’s Confidential Information, then subject to clause 9(d), the applicant seeking to Publish must remove such Confidential Information from the Publication prior to
Publishing the relevant work. 

  

	 	(d)	If a Student thesis includes Confidential Information, notwithstanding any other provision of this Agreement: 

  

	 	(i)	the thesis may be distributed to the candidate’s examiners, on a confidential basis; and 

  

	 	(ii)	copies of the thesis will be maintained only in the “restricted” section of the library of the educational institution of which the candidate is a student for a period of 12 months from the date of the award
of the degree. 

  

	 	(e)	Any Publication (including any Student Publication) must acknowledge the support of the Commonwealth in accordance with clause 3.9. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 24	 

	10.	Protection of personal information 

  

	10.1	Definitions 

 In this clause 10 and Schedule 6: 

 

	 	(a)	the terms ‘agency’, ‘Australian Privacy Principle’ (APPs), ‘APP privacy policy’ and ‘Australian Privacy Principle Code’ (APP code) have the same meaning as they have
in section 6 of the Privacy Act 1988 (Cth) (Privacy Act) , and ‘personal information’, which also has the meaning it has in section 6 of the Privacy Act, means: 

‘information or an opinion about an identified individual, or an individual who is reasonably identifiable whether the information or
opinion is true or not and whether the information or opinion is recorded in a material form or not’. 
  

	 	(b)	‘Privacy Laws’ means all Laws relating to the privacy, confidentiality or use of any information about individuals, including the Privacy Act. 

 

	10.2	Application of this clause 

  

	 	(a)	Where the Participant deals with personal information provided by the Commonwealth for the purpose of completing the Project under this Agreement the terms of Schedule 6 will apply with respect to that personal
information. 

  

	 	(b)	Where the Participant deals with personal information provided for the purpose of completing the Project under this Agreement, other than information provided by the Commonwealth, the terms of clause 10.3 will apply
with respect to that personal information. 

  

	10.3	Personal Information other than Commonwealth provided Personal Information 

  

	 	(a)	Each Party must: 

  

	 	(i)	comply with all Privacy Laws for the collection, storage, use and disclosure of personal information as required in order for the Parties to comply with their obligations under this Agreement; 

 

	 	(ii)	not do anything with any personal information collected by it in connection with this Agreement that will cause any other Party to breach any Privacy Laws; and 

 

	 	(iii)	co-operate with each other Party to resolve any privacy complaint by any person. 

  

	 	(b)	Each Party will be responsible for determining and monitoring its own compliance with all applicable Privacy Laws. 

  

	 	(c)	Each Party will indemnify each other Party for any claims, loss or damage the indemnified party may incur as a result of the indemnifying party’s failure to comply with any obligation under this clause 10.3 or any
requirements under Privacy Laws. 

  

	11.	Insurance 

  

	11.1	Obligation to maintain insurance 

 In connection with the Project, each Participant must
have and maintain: 
  

	 	(a)	workers’ compensation insurance for an amount required by the relevant State or Territory legislation; 

  

	 	(b)	public liability insurance for an adequate amount per claim, or occurrence giving rise to a claim, in respect of activities undertaken under this Agreement (where occurrence means either a single occurrence or a series
of occurrences if these are linked or occur in connection with one another from one original cause, as the case may be); 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 25	 

	 	(c)	insurance over any Asset acquired pursuant to clause 14 of the Funding Agreement for its full replacement value; and 

  

	 	(d)	any other insurance required by Law or by the Commonwealth (acting reasonably). 

  

	11.2	Certificates of Currency 

 Each Participant must, within 10 Business Days of a request
from the Commonwealth or other Participants, provide a current relevant confirmation of insurance documentation from its insurers or insurance brokers certifying that it has insurance as required by clause 11.1. 

 

	11.3	Self-Insurance or other protection 

 Proof of adequate levels of self-insurance or other
protection by a Party are acceptable as an alternative to the insurances required under clause 11.1. 
  

	12.	Work health and safety 

 Each Participant must: 

 

	 	(a)	ensure the Project is undertaken in a safe manner; 

  

	 	(b)	ensure that their Personnel do not, by act or omission, place the Commonwealth in breach of its obligations under the WHS Laws; and 

  

	 	(c)	ensure that their Personnel, if using or accessing the Commonwealth’s premises or facilities, comply with all reasonable instructions, directions, policies and procedures relating to work health and safety in
operation at those premises or facilities whether specifically drawn to the attention of the Participant or which might reasonably be inferred from the circumstances. 

 

	13.	Conflict of Interest 

  

	13.1	Warranty 

 Each Participant warrants that, to the best of its knowledge after making
diligent inquiry, at the date of signing this Agreement, no conflict of interest exists or is likely to arise in the performance of its obligations under this Agreement. 

 

	13.2	Notification of a conflict of interest 

 If, during the Agreement Period, a conflict of
interest arises, or appears likely to arise, each Participant must: 
  

	 	(a)	notify the Lead Participant or the Commonwealth immediately in writing; 

  

	 	(b)	make full disclosure of all relevant information relating to the conflict; and 

  

	 	(c)	take such steps as the Commonwealth or the Lead Participant requires to resolve or otherwise deal with the conflict. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 26	 

	14.	Books and records 

  

	14.1	Participant to keep books and records 

 Each Participant must: 

 

	 	(a)	keep adequate books and records, in accordance with Accounting Standards, in sufficient detail to enable: 

  

	 	(i)	all receipts and payments related to the Project to be identified and reported in accordance with this Agreement; and 

  

	 	(ii)	the amounts payable by the Commonwealth under the Funding Agreement to be determined; and 

  

	 	(b)	retain for a period of seven years after the expiry or termination of this Agreement, all books and records relating to the Project. 

 

	14.2	Reports 

 On or before the last day of each Quarter during the Agreement Period, each
Project Partner must provide to the Lead Participant, an itemised report for the previous Quarter of: 
  

	 	(a)	all money received from the Lead Participant and all expenditure associated with the Project, detailed as against each head of expenditure; 

 

	 	(b)	an overview of any Milestones and Outcomes achieved in that Quarter, and/or an evaluation of progress in achieving upcoming scheduled Milestones; 

 

	 	(c)	a list of any changes to Project Partner structure/ownership/involvement, Agreement Material, key personnel or other matters which could affect compliance with this Agreement; 

 

	 	(d)	a report in respect of that Quarter on the in-kind contributions (staff and non-staff in-kind)
contributed to the Project by the Project Partner; and 

  

	 	(e)	a declaration by the Project Partner certifying the accuracy of the particulars provided under paragraphs (a) to (d), including a statement that the CRC-P Funds have been
expended only for the Project and otherwise in accordance with this Agreement. 

  

	14.3	Costs 

 Each Participant must bear its own costs of complying with this clause 14. 

 

	15.	Monitoring progress 

  

	 	(a)	The Project Partners will provide reasonable assistance and information in relation to the Project in order for the Lead Participant to meet with the Commonwealth to discuss any issues in relation to the Project (at the
times and dates required by the Commonwealth). 

  

	 	(b)	The Project Partners must provide the Lead Participant with all reasonable assistance and information required for the Lead Participant to complete the reports required to be submitted to the Commonwealth in accordance
with the Funding Agreement. 

  

	 	(c)	If the Commonwealth conducts a review of the CRC Project in accordance with the Funding Agreement the Project Partners must provide all reasonable assistance to the Lead Participant for the Lead Participant to respond
to such review, or take any action required pursuant to such review including (where applicable): 

  

	 	(i)	undertaking any evaluation of the: 

  

	 	(A)	performance of the CRC Project; and 

  

	 	(B)	conduct of the Project; 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 27	 

	 	(ii)	completing surveys, questionnaires and other evaluation procedures related to the performance of the Project Partners, the CRC-P or the Programme; 

 

	 	(iii)	preparation of reports reasonably required by the Commonwealth; and 

  

	 	(iv)	responding to reasonable requests of the Commonwealth and providing information reasonably required by the Commonwealth. 

  

	16.	Participants audit and access 

  

	 	(a)	Each Project Partner must ensure that authorised representatives of the Lead Participant have full access to each of its premises used for the conduct of the Project during ordinary business hours for the purpose of
generally ensuring compliance with the requirements of the Project and this Agreement, provided that the Lead Participant provides at least 5 Business Day’s Notice. Such authorised representatives may examine and copy any books and
records maintained in relation to the performance of the Project conducted at that premises. 

  

	 	(b)	The Lead Participant will allow the authorised representatives of each Project Partner to examine any books and records maintained by the Lead Participant relation to the performance of the Project conducted at its
premises during ordinary business hours provided that the Project Partner provides at least 5 Business Day’s Notice. 

  

	17.	Commonwealth audit and access 

  

	17.1	Right to conduct audits 

 The Participants agree that the Commonwealth, or a
representative of the Commonwealth, may conduct audits relevant to the performance of a Participant’s obligations under this Agreement. Audits may be conducted of: 
  

	 	(a)	the Assets; 

  

	 	(b)	the Participant’s operational practices and procedures as they relate to this Agreement or the Funding Agreement; 

  

	 	(c)	the accuracy of the Participant’s invoices and reports; 

  

	 	(d)	the Participant’s compliance with its confidentiality and privacy obligations under this Agreement; 

  

	 	(e)	Material (including books and records) in the possession of the Participant relevant to the Project or this Agreement; and 

  

	 	(f)	any other matters determined by the Commonwealth to be relevant to the Project or this Agreement. 

  

	17.2	Access by the Commonwealth 

  

	 	(a)	The Participants agree that the Commonwealth, or a representative of the Commonwealth, may, at reasonable times and on giving reasonable Notice to the Participants: 

 

	 	(i)	access the premises of the Participants to the extent relevant to the performance of this Agreement; 

  

	 	(ii)	require the provision by the Participants or its Personnel of records and information in a data format and storage medium accessible by the Commonwealth by use of the Commonwealth’s existing computer hardware and
software; 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 28	 

	 	(iii)	inspect and copy documentation, books and records, however stored, in the custody or under the control of the Participants or its Personnel; and 

 

	 	(iv)	require assistance in respect of any inquiry into or concerning the Project or this Agreement. For these purposes, an inquiry includes any administrative or statutory review, audit or inquiry (whether within or external
to the Department of Industry, Innovation and Science), any request for information directed to the Commonwealth, and any inquiry conducted by Parliament or any Parliamentary committee. 

 

	 	(b)	The Participants agree that they will provide access to their computer hardware and software to the extent necessary for the Commonwealth to exercise its rights under this clause 17, and provide the Commonwealth with
any reasonable assistance requested by the Commonwealth to use that hardware and software. 

  

	17.3	Auditor-General and the Australian Information Commissioner 

 The Participants agree that
the rights of the Commonwealth under clause 17.2(a)(i) to 17.2(a)(iii) apply equally to the Auditor General or a delegate of the Auditor-General, or the Australian Information Commissioner or a delegate of the Australian Information Commissioner,
for the purpose of performing the Auditor-General’s or Australian Information Commissioner’s statutory functions or powers. 
  

	17.4	Participants to comply with Auditor-General’s requirements 

 Each Participant must
do all things necessary to comply with the Auditor-General’s or his or her delegate’s or the Australian Information Commissioner’s or his or her delegate’s requirements, notified to the Participant under clause 17.2, provided
such requirements are legally enforceable and within the power of the Auditor-General, the Australian Information Commissioner, or his or her respective delegate. 
  

	17.5	No reduction in responsibility 

 The requirement for, and participation in, audits does
not in any way reduce each Participant’s responsibility to perform their obligations in accordance with this Agreement. 
  

	17.6	Subcontractor requirements 

 Each Participant must ensure that any subcontract entered
into for the purpose of this Agreement contains an equivalent clause granting the rights specified in this clause 17. 
  

	17.7	No restriction 

 The Participants agree that nothing in this Agreement reduces, limits or
restricts in any way any function, power, right or entitlement of the Auditor-General or a delegate of the Auditor-General or the Australian Information Commissioner or a delegate of the Office of the Australian Information Commissioner. The
Participants agree that the rights of the Commonwealth under this Agreement are in addition to any other power, right or entitlement of the Auditor-General or a delegate of the Auditor-General or the Australian Information Commissioner or a delegate
of the Australian Information Commissioner. 
  

	17.8	Costs 

 Unless otherwise agreed in writing, the Participants must bear their own costs of
any reviews and/or audits by the Commonwealth. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 29	 

	18.	False or misleading information 

 Each Participant: 

 

	 	(a)	acknowledges that giving false or misleading information to the Commonwealth is a serious offence under section 137.1 of the Criminal Code Act 1995 (Criminal Code); and 

 

	 	(b)	must ensure that all of its Personnel engaged in connection with this Agreement acknowledges the information contained in this clause. 

Note: Under section 137 of the Criminal Code giving false or misleading information to a Commonwealth entity is an offence, but only if the
Commonwealth entity took reasonable steps to inform the person of the offence. 
  

	19.	Safe and Ethical Research 

 When research in Australia is conducted on or involving humans or
animals, each Participant will support the CRC-P in meeting its obligations in regards to compliance with safe and ethical research by ensuring that: 

 

	 	(a)	the research complies with, and observes, all relevant ethics codes and guidelines adopted by the National Health and Medical Research Council, the Office of the Gene Technology Regulator and all other relevant
regulatory agencies operating in Australia and any place in which the research is being conducted being codes and guidelines in force from time to time during the Agreement Period, including requirements to obtain prior approval in writing
(including from any relevant ethics committee) that the research to be undertaken is so compliant; 

  

	 	(b)	one or several higher education institution(s), or Commonwealth or State research organisation(s), or medical institution(s) with a relevant ethics committee constituted in accordance with the codes and guidelines
referred to in clause 20(a) is engaged to oversee all ethical clearances which may be required under those codes and guidelines; 

  

	 	(c)	when conducting research in Australia which involves the use of ionising radiation, that persons performing procedures involving ionising radiation are appropriately trained and hold a relevant current licence from the
appropriate State authority; and 

  

	 	(d)	whenever reasonably required by the Lead Participant, a Project Partner will promptly furnish written evidence of compliance with the requirements of this clause 19. 

 

	20.	Responsible conduct of research 

  

	 	(a)	Each Participant must ensure that the research conducted by it conforms to the principles outlined in the following and successor documents: 

 

	 	(i)	the NHMRC/ARC/UA Australian Code for the Responsible Conduct of Research (2007); and 

  

	 	(ii)	if applicable, the NHMRC/ARC/AVCC National Statement on Ethical Conduct in Human Research (2007). 

  

	 	(b)	Each Participant agrees that it will: 

  

	 	(i)	promote the responsible conduct of research; 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 30	 

	 	(ii)	maintain high standards of responsible research; 

  

	 	(iii)	report research responsibly; 

  

	 	(iv)	respect all research participants; 

  

	 	(v)	respect animals used in research; 

  

	 	(vi)	respect the environment; and 

  

	 	(vii)	report research misconduct. 

  

	 	(c)	Each Participant must have procedures in place for dealing with instances of suspected or alleged research misconduct which are consistent with the codes and guidelines referred to in clause 20(a). 

 

	21.	Survival 

 The following clauses survive the expiry or termination of this Agreement: 

 

	 	(a)	Clause 3.1(h) (General Obligations); 

  

	 	(b)	Clause 3.4 (Subcontract) 

  

	 	(c)	Clause 3.9 (Acknowledgement of support); 

  

	 	(d)	Clause 4 (Intellectual Property Rights); 

  

	 	(e)	Clause 6 (Repayment); 

  

	 	(f)	Clause 8 (Confidentiality); 

  

	 	(g)	Clause 9 (Publication Policy); 

  

	 	(h)	Clause 10 (Protection of personal information); 

  

	 	(i)	Clause 11 (Insurance); 

  

	 	(j)	Clause 14 (Books and records) for a period of seven years from the expiry or termination of the Funding Agreement; 

  

	 	(k)	Clause 16 (Participant Audit and Access) for a period of seven years from expiry or termination of the Funding Agreement; 

  

	 	(l)	Clause 17 (Commonwealth Audit and access) for a period of seven years from the expiry or termination of the Funding Agreement, and 

  

	 	(m)	Clause 24 (Agreement Period and Termination), 

 together with any provision of this Agreement
which expressly or by implication from its nature is intended to survive the expiry or termination of this Agreement. 
  

	22.	Changes to the Agreement 

 No agreement or understanding varying this Agreement shall be legally
binding unless it is signed in writing by all Parties. 
  

	23.	Relationship to the Funding Agreement 

  

	 	(a)	Nothing in this Agreement will reduce or otherwise affect the obligations of the Lead Participant under the Funding Agreement. In the event of any inconsistency between this Agreement and the Funding Agreement, the
Funding Agreement takes precedence. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 31	 

	 	(b)	Notwithstanding any other provision of this Agreement, the Parties acknowledge and agree that if any funding is reduced or suspended under the Funding Agreement, any amount payable under this Agreement will be
correspondingly reduced or suspended. 

  

	24.	Agreement Period and Termination 

  

	24.1	Agreement Period 

 This Agreement commences on the Commencement Date and will end on the
later of: 
  

	 	(a)	31st December 2020; or 

  

	 	(b)	the date on which all reporting requirements relating to the Project under the Funding Agreement have been met, 

unless otherwise terminated in accordance with this Agreement. 
  

	24.2	Change of Project Partner 

  

	 	(a)	Subject to clause 24.2(c), the Lead Participant may, acting reasonably, elect to remove from the Project a Project Partner by providing written Notice to that Project Partner, with a copy to all other Project Partners
and the Commonwealth. 

  

	 	(b)	A change of Project Partners is subject to the Lead Participant gaining the Commonwealth’s approval under clause 5.7 of the Funding Agreement. 

 

	 	(c)	The Lead Participant may remove a Project Partner from the Project with immediate effect by written Notice to the Project Partner, if: 

 

	 	(i)	the Project Partner breaches any provision of this Agreement and fails to remedy the breach within 14 days after receiving Notice requiring it to do so; 

 

	 	(ii)	the Project Partner breaches a provision of this Agreement which is not capable of remedy; 

  

	 	(iii)	the Project Partner persistently breaches a provision of this Agreement despite Notice of the breach; 

  

	 	(iv)	in the reasonable opinion of the Lead Participant, the Project Partner is not conducting the Project in a competent and diligent manner; 

 

	 	(v)	the Project Partner fails to notify the Lead Participant of a conflict of interest, or in the opinion of the Lead Participant, a conflict of interest exists which: 

 

	 	(A)	would prevent the Project Partner from performing its obligations under this Agreement; or 

  

	 	(B)	could prejudice the Utilisation of Agreement Material by the Lead Participant. 

  

	 	(vi)	the Lead Participant is unable to obtain Contributions from the Project Partner in accordance with Schedule 3, or obtain them in time to provide for the Outcomes, activities or Milestones as outlined in the Schedule 2;

  

	 	(vii)	the Project Partner rejects the Lead Participant’s reasonable request for a Work Order on 3 or more occasions; 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 32	 

	 	(viii)	the Project Partner does not comply with a Commonwealth direction, requiring the Project Partner to comply with any obligation owed to the Commonwealth under this Agreement; or 

 

	 	(ix)	an event specified in clause 24.2(d) occurs. 

  

	 	(d)	The Project Partner must notify the Lead Participant immediately if: 

  

	 	(i)	there is any change in the direct or indirect beneficial ownership or control of the Project Partner; 

  

	 	(i)	the Project Partner disposes of the whole or any part of its assets, operations or business other than in the ordinary course of business; 

 

	 	(ii)	the Project Partner ceases to carry on business; 

  

	 	(iii)	the Project Partner ceases to be able to pay its debts as they become due; 

  

	 	(iv)	proceedings are initiated with a view to obtaining an order for the winding up of the Project Partner, or any person convenes a meeting for the purpose of considering or passing any resolution for the winding up of the
Project Partner; 

  

	 	(v)	the Project Partner applies to come under, the Project Partner receives a notice requiring it to show cause why it should not come under, an order has been made for the purpose of placing the Project Partner under, or
the Project Partner otherwise comes under one of the forms of external administration referred to in Chapter 5 of the Corporations Act 2001 (Cth) or Chapter 11 of the Corporations (Aboriginal and Torres Strait Islander) Act 2006 (Cth)
or equivalent provisions in State or Territory legislation in relation to incorporated associations; 

  

	 	(vi)	the Project Partner being a natural person is declared bankrupt or assigns his or her estate for the benefit of creditors; 

  

	 	(vii)	where the Project Partner is a partnership, any step is taken to dissolve that partnership; or 

  

	 	(viii)	anything analogous to an event referred to in clause 24.2(d)(iv) – (vii) occurs in relation to the Project Partner. 

  

	24.3	Withdrawal of a Project Partner from the Agreement 

  

	 	(a)	A Project Partner may, acting reasonably, submit a request to withdraw from the Agreement by providing written Notice to the Lead Participant, with a copy to all other Project Partners and the Commonwealth if:

  

	 	(i)	the Lead Participant or other Project Partner is in material breach of this Agreement, and such breach has not been rectified within 30 days of Notice of the breach or the breach is incapable of remedy;

  

	 	(ii)	an event referred to in clause 24.2(d)(iii) – (viii) occurs in relation to the Project Partner; 

  

	 	(iii)	the Lead Participant: 

  

	 	(A)	ceases to carry on business; or 

  

	 	(B)	ceases to be able to pay its debts as they become due; 

  

	 	(iv)	proceedings are initiated with a view to obtaining an order for the winding up of the Lead Participant, or any person convenes a meeting for the purpose of considering or passing any resolution for the winding up of the
Lead Participant; or 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 33	 

	 	(v)	the Lead Participant applies to come under, or receives a notice requiring it to show cause why it should not come under, an order has been made for the purpose of placing the Lead Participant under, or the Lead
Participant otherwise comes under one of the forms of external administration referred to in Chapter 5 of the Corporations Act 2001 (Cth) or Chapter 11 of the Corporations (Aboriginal and Torres Strait Islander) Act 2006 (Cth) or equivalent
provisions in State or Territory legislation in relation to incorporated associations. 

  

	 	(b)	If a Project Partner requests withdrawal in accordance with clause 24.3(a), the Lead Participant must apply to the Commonwealth for the Project Partner to be removed in accordance with clause 5.7 the Funding Agreement.

  

	 	(c)	If the Commonwealth agrees to remove the Project Partner in accordance with clause 5.7 the Funding Agreement, the Lead Participant will give Notice to the Project Partners, and the relevant Project Partner will be
automatically removed. 

  

	24.4	Consequences of removal of a Project Partner 

  

	 	(a)	If a Project Partner is removed from the Project pursuant to clause 24.2 or 24.3, this Agreement will continue as between the Lead Participant and remaining Project Partner. 

 

	 	(b)	If a Project Partner is removed from the Project pursuant to clause 24.2 or 24.3, it: 

  

	 	(i)	is not entitled to reimbursement of any costs incurred as a result of removal; 

  

	 	(ii)	must assign its share of ownership of the Agreement Material and all Intellectual Property Rights in such material in accordance with Schedule 5 or as otherwise agreed in writing by the Participants; and

  

	 	(iii)	grants to the other Participants and Commonwealth a world-wide, irrevocable, perpetual royalty–free non-exclusive licence (including the right to sublicense) to use,
reproduce, adapt, modify and communicate any of its Pre-existing Material or Third Party Material provided for the purpose of the Project subject to any limitations provided in clause 4.1(h) and (i);

  

	 	(c)	Removal will not affect the enforceability of any rights or obligations accrued under this Agreement which survive termination. 

  

	 	(d)	From the date of removal, the Lead Participant will cease to be liable to pay or provide to the removed Project Partner any monies due under this Agreement, except to the extent those monies have been legally committed
for expenditure by the Project Partner in accordance with this Agreement and are payable by the Project Partner as a current liability (written evidence of which will be required) before the date on which the Project Partner receives Notice of the
removal. 

  

	 	(e)	From the date of removal, the removed Project Partner will cease to be liable to make any Contribution to the Project scheduled to be made after the removal date. 

 

	 	(f)	From the date of removal, the Lead Participant is entitled to recover from the removed Project Partners any CRC-P Funds provided by the Lead Participant to a Project Partner which
have not been spent, or legally committed for expenditure by the Project Partner in accordance with this Agreement and payable by the Project Partner as a current liability (written evidence of which will be required) by the date the Project Partner
receives the Notice of termination; and 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 34	 

	24.5	Termination of this Agreement for default 

 The Lead Participant may terminate this
Agreement with immediate effect by written Notice to the other Project Partners if any of the events detailed in clauses 24.2(c)(i) to (viii) occur. 
  

	24.6	Termination by Notice 

 The Lead Participant may terminate this Agreement with immediate
effect by written Notice where the Commonwealth terminates the Funding Agreement. 
  

	24.7	Suspension 

 If the Commonwealth suspends payment of the Funds in accordance with the
Funding Agreement, the Parties must continue to comply with the terms of this Agreement. 
  

	24.8	Consequences of termination– Intellectual Property 

 If the Lead Participant
terminates this Agreement under clause 24.5 or 24.6, all Participants must assign their share of ownership of the Agreement Material and all Intellectual Property Rights in such material in accordance with Schedule 5. 

 

	24.9	Other consequences of termination 

 If the Lead Participant terminates this Agreement
under clause 24.5 or 24.6: 
  

	 	(a)	termination will not affect the enforceability of any rights or obligations accrued under this Agreement which survive termination; 

  

	 	(b)	the Lead Participant is not obliged to pay to the Project Partners any outstanding amount of the monies due under this Agreement, except to the extent that those monies have been legally committed for expenditure by the
Project Partner in accordance with this Agreement and payable by the Project Partner as a current liability (written evidence of which will be required) by the date the Project Partner receives the Notice of termination; 

 

	 	(c)	as of the date the Project Partners receive the Notice of termination, the Participants will cease to be liable to make further Contributions to the Project; and 

 

	 	(d)	the Lead Participant is entitled to recover from Project Partners any CRC-P Funds provided by the Lead Participant to a Project Partner which have not been spent, or legally
committed for expenditure by the Project Partner in accordance with this Agreement and payable by the Project Partner as a current liability (written evidence of which will be required), by the date the Project Partner receives the Notice of
termination. 

  

	25.	Liability and Indemnity 

  

	25.1	Indemnity 

 Each Project Partner will at all times indemnify, hold harmless and defend
the Lead Participant, its officers and employees (referred to in this clause 25 as “those indemnified”) from and against any loss or liability, including: 
  

	 	(a)	loss arising from loss of, or damage to, property of the Commonwealth; 

  

	 	(b)	claims by any person in respect of personal injury or death; 

  

	 	(c)	claims by any person in respect of loss of, or damage to, any property; and 

  

	 	(d)	costs and expenses including the costs of defending or settling any claim referred to in clause 25.1(b) or clause 25.1(c), 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 35	 

 arising out of or as a consequence of the Project Participant’s (or its Personnel’s):

  

	 	(a)	use or disposal of Assets; 

  

	 	(b)	infringement, or alleged infringement, of the Intellectual Property Rights of any person; 

  

	 	(c)	actual, likely or threatened breach of its obligations relating to Confidential Information or personal information; or 

  

	 	(d)	without limiting the preceding paragraphs, breach of this Agreement, or negligence or wrongful or unlawful act or omission. 

The Project Partner’s liability to indemnify those indemnified under clause 25 will be reduced proportionally to the extent that any
negligent act or omission of those indemnified contributed to the loss. 
  

	25.2	Consequential loss 

 The Lead Participant is not liable to any Project Partner or to any
other person for any indirect, incidental, special or consequential loss or damage, loss of profits or anticipated profits, economic loss, loss of business opportunity, loss of data or loss or damage resulting from wasted management time
irrespective of whether: 
  

	 	(a)	the loss or damage is caused by or relates to breach of contract, statute, tort (including negligence) or otherwise; or 

  

	 	(b)	the Parties or any other person previously were notified of the possibility of the loss or damage. 

  

	25.3	Maximum liability 

 The Lead Participant’s maximum liability under this Agreement
will be capped at an aggregate of XXXX. 
  

	26.	Dispute resolution 

  

	26.1	No arbitration or court proceedings 

 If a dispute arises in relation to the conduct of
this Agreement (Dispute), a Party must comply with this clause 26 before starting arbitration or court proceedings except proceedings for urgent interlocutory relief. After a Party has sought or obtained any urgent interlocutory relief, that
Party must follow this clause 26. 
  

	26.2	Notification 

 A Party claiming a Dispute has arisen must give the other Parties to the
Dispute Notice setting out details of the Dispute. 
  

	26.3	Parties to resolve Dispute 

 During the 14 days after a Notice is given under clause 26.2
(or longer period if the parties to the Dispute agree in writing), each party to the Dispute must use its reasonable efforts through a meeting of CEOs (or their nominees) to resolve the Dispute. If the parties cannot resolve the Dispute within that
period, they must refer the Dispute to a mediator if one of them requests. 
  

	26.4	Appointment of mediator 

 If the parties to the Dispute cannot agree on a mediator within
seven days after a request under clause 26.3, the chairperson of the Resolution Institute or the chairperson’s nominee will appoint a mediator. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 36	 

	26.5	Role of mediator and obligations of parties 

 The role of a mediator is to assist in
negotiating a resolution of the Dispute. A mediator may not make a binding decision on a party to the Dispute except if the party agrees in writing. Unless agreed by the mediator and parties, the mediation must be held within 21 days of the request
for mediation in clause 26.3. The parties must attend the mediation and act in good faith to genuinely attempt to resolve the Dispute. 
  

	26.6	Confidentiality 

 Any information or documents disclosed by a party under this clause 26:

  

	 	(a)	must be kept confidential; and 

  

	 	(b)	may only be used to attempt to resolve the Dispute. 

  

	26.7	Costs 

 Each party to a Dispute must pay its own costs of complying with this clause 26.
The parties to the Dispute must equally pay the costs of any mediator. 
  

	26.8	Termination of process 

 A Party to a Dispute may terminate any mediation process
commenced under this clause 26 by giving Notice to each other party provided it has otherwise complied with this clause 26.Clauses 26.6 and 26.7 survive termination of the mediation process. 

 

	27.	Notices and other communications 

  

	27.1	Service of Notices 

 A Notice must be: 

 

	 	(a)	in writing, in English and signed by a person duly authorised by the sender; and 

  

	 	(b)	hand delivered or sent by prepaid post or by electronic means (facsimile or email) to the Participant address for Notices specified in item 8 of Schedule 1, as varied by any Notice given by the Participant.

  

	27.2	Effective on receipt 

 A Notice given in accordance with clause 27.1 takes effect when it
is taken to be received (or at a later time specified in it), and is taken to be received: 
  

	 	(a)	if hand delivered, on delivery; 

  

	 	(b)	if sent by prepaid post, on the second Business Day after the date of posting (or on the seventh Business Day after the date of posting if posted to or from a place outside Australia); 

 

	 	(c)	if sent by facsimile, when the sender’s facsimile system generates a message confirming successful transmission of the entire Notice unless, within eight ordinary business hours after the transmission, the
recipient informs the sender that it has not received the entire Notice; or 

  

	 	(d)	if sent by email, as provided under sections 14 and 14A of the Electronic Transactions Act 1999 (Cth), 

but if the delivery, receipt or transmission is not on a Business Day or is after 5.00 pm on a Business Day, the Notice is taken to be received
at 9.00am on the next Business Day. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 37	 

	28.	Miscellaneous 

  

	28.1	No security 

 A Participant must not use any of the following as any form of security for
the purpose of obtaining or complying with any form of loan, credit, payment or other interest, or for the preparation of, or in the course of any litigation: 
  

	 	(a)	the CRC-P Funds; or 

  

	 	(b)	any Assets or Agreement Material. 

  

	28.2	Nature of obligations 

  

	 	(a)	Any provision in this Agreement which binds more than one person binds all each of those persons severally and does not bind them jointly. 

 

	 	(b)	Each obligation imposed on a Party by this Agreement in favour of another is a separate obligation. 

  

	28.3	No adverse construction 

 This Agreement, and any provision of this Agreement, is not to
be construed to the disadvantage of a party because that party was responsible for its preparation. 
  

	28.4	Approvals and consents 

 Except where this Agreement expressly states otherwise, a Party
may, in its discretion, give conditionally or unconditionally or withhold any approval or consent under this Agreement. 
  

	28.5	Assignment and novation 

 A Party may only assign its rights or novate its rights and
obligations under this Agreement with the prior written consent of the other party. 
  

	28.6	Costs 

 Each Party must pay its own costs of negotiating, preparing and executing this
Agreement. 
  

	28.7	Counterparts 

 This Agreement may be executed in counterparts. All executed counterparts
constitute one document. 
  

	28.8	No merger 

 The rights and obligations of the parties under this Agreement do not merge
on completion of any transaction contemplated by this Agreement. 
  

	28.9	Entire agreement 

 This Agreement constitutes the entire agreement between the Parties in
connection with its subject matter and supersedes all previous agreements or understandings between the Parties in connection with its subject matter. 
  

	28.10	Further action 

 Each Party must do, at its own expense, everything reasonably necessary
(including executing documents) to give full effect to this Agreement and any transaction contemplated by it. 
  

	28.11	Severability 

 A term or part of a term of this Agreement that is illegal or
unenforceable may be severed from this Agreement and the remaining terms or parts of the terms of this Agreement continue in force. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 38	 

	28.12	Waiver 

 Waiver of any provision of or right under this Agreement: 

 

	 	(a)	must be in writing signed by the Party entitled to the benefit of that provision or right; and 

  

	 	(b)	is effective only to the extent set out in any written waiver. 

 A waiver of a breach does not
operate as a waiver of any other breach. 
  

	28.13	Governing law and jurisdiction 

 This Agreement is governed by the law of the Australian
Capital Territory and each party irrevocably and unconditionally submits to the non-exclusive jurisdiction of the courts of the Australian Capital Territory. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 39	 

 Schedule 1 – CRC-P Details 

 
  

							
	 Item 

number
	  	Issue	  	Clause
Reference	  	 Details

	 1.
	  	Project Title	  	Background A	  	Targeting Tropomyosin as a Novel Anti-Cancer Therapy
				
	 2.
	  	Guidelines	  	1 and 3.1	  	The Cooperative Research Centres Programme Guidelines, and any related documentation developed to assist the management and administration of the CRC Programme, issued by the Commonwealth and as amended from time to time.
				
	 3.
	  	Pre-existing
Material	  	1 and 4.1	  	 Lead Participant pre-existing material

 
 All pre-existing data generated by the Lead
Participant’s sponsored research in pursuit of tropomyosin binding compounds that are relevant to the aims of the Project.
  

All other techniques, know-how, software and materials (regardless of the form or medium in which they are disclosed or
stored) that are provided by or on behalf of the Lead Participant for use in the Project.
  

Participant UNSW pre-existing material

 
 All techniques, know-how, software and materials
(regardless of the form or medium in which they are disclosed or stored) that are provided by or on behalf of UNSW for use in the Project.
  

Participant ICP Firefly pre-existing material

 
 All techniques, know-how, software and materials
(regardless of the form or medium in which they are disclosed or stored) that are provided by or on behalf of ICP Firefly for use in the Project.

				
	 4.
	  	Third Party
Material	  	1 and 4.1	  	None
				
	 5.
	  	Intellectual
 Property/Agreement
Material
	  	1 and 4.1	  	IP arrangements and Utilisation of Agreement Material are detailed in Schedule 5.
				
	 6.
	  	Confidential
Information	  	1 and 8	  	 Lead Participant’s Confidential Information
  

1.      The Participants Agreement (period of time: in
perpetuity);

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 40	 

							
		  		  		  	 2.      the Lead Participant’s
Pre-existing Material; and
  

3.      All Novogen Material and reports required to be provided to the Commonwealth
under
          the Funding Agreement.

 
 For the Novogen Material and Pre-existing
Material, the period of confidentiality persists until: (1) notified by the Lead Participant that the contents therein have sufficient intellectual property protection to ensure that disclosure could offer no detriment to commercial gain, or
(2) notified by the Lead Participant that the contents therein are no longer subject to confidentiality because of prior disclosures or discontinuance of work on the subject matter; or (3) the information is otherwise publically available
other than through breach of this Agreement or other confidentiality obligation.
  

UNSW’s Confidential Information
  

1.      UNSW’s Pre-existing Material;

 
 2.      the
Technical Assays Material; and
  
 For the Technical Assays Material and Pre-existing Material, the period of confidentiality persists until: (1) notified by UNSW that the contents therein have sufficient intellectual property protection to ensure that disclosure could offer no
detriment to commercial gain; or (2) notified by UNSW that the contents therein are no longer subject to confidentiality because of prior disclosures or discontinuance of work on the subject matter; or (3) the information is otherwise
publically available other than through breach of this Agreement or other confidentiality obligation.
  

ICP Firefly Confidential Information
  

1.      ICP Firefly’s Pre-existing
Material
  
 For Pre-existing Material, the
period of confidentiality persists until: (1) notified by ICP Firefly that the contents therein have sufficient intellectual property protection to ensure that disclosure could offer no detriment to commercial gain; or (2) notified by ICP
Firefly that the contents therein are no longer subject to confidentiality because of prior disclosures or discontinuance of work on the subject matter; or (3) the information is otherwise publically available other than through breach of this
Agreement or other confidentiality obligation.

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 41	 

							
	7.	  	Specified
Personnel	  	Clause 1.1, 3.5	  	 Novogen
  

Dr S Palmer Program Director 0.8xFTE
 Dr J Hook UNSW Research
Officer 1.0xFTE
  
 ICP Firefly

 
 Dr I Meyer-Carrive 0.1xFTE

 
 UNSW Australia

 
 Prof. P Gunning 0.1xFTE

				
	8.	  	Notice details	  	Clause 27	  	 Novogen:
  

Dr Stephen Palmer
 Program Director

Novogen Ltd
  

PO BOX 2333
 Hornsby Westfield

Hornsby NSW 1635
  

Suite 502
 20 George Street

Hornsby NSW 2077
  

Email: stephen.palmer@novogen.com
  

UNSW:
  

Professor Peter Gunning
 Head of School

School of Medical Sciences
 Wallace Wurth East

University of New South Wales
 Kensington NSW 2052

Email: p.gunning@unsw.edu.au
  

ICP Firefly:
  

Dr Isabelle Meyer-Carrive
 Managing Director/CEO

129 Queen Street
 Beaconsfield NSW 2015

Email: isabelle@icpfirefly.com.au

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 42	 

 Schedule 2 – Project Details 

 
  

	1.	Project Overview, Outcomes and impacts (clause 1 and 3.1) 

 Cancer therapies have a global market value of
$50bn/year, growing 6%/annum with constant demand for new treatments. This project aims to provide improved chemotherapy for advanced metastatic disease through an Australian innovation to selectively destroy cancer cells using anti-tropomyosin
(ATM) drugs. Prototype ATMs have demonstrated proof of concept in model systems but CRC-P investment is needed to perfect this technology and create a clinical product with high commercial value. The key
activities include protein structure research and computer-aided modelling of the target protein, manufacture and screening of compounds designed to fit and to disrupt the function of the target protein, refinement of pharmaceutic properties and
drug delivery methods, advancement to screening and testing in animal models of cancer to demonstrate evidence of efficacy and completion of all of the standard toxicology tests required for submission of an Investigational New Drug (IND)
application to the FDA. The project outcomes will be a novel anti-cancer drug with a scalable manufacturing strategy, an established delivery route, an understanding of which cancer types are most susceptible to this drug (influencing clinical
strategy) and a comprehensive portfolio of preclinical evidence supporting treatment of advanced metastatic disease. At project end, the drug will have all of the regulatory compliance data required for entry into clinical trials, with the aim of
establishing clinical efficacy within a further 3 years (end of phase II) allowing subsequent licensing deals with multinational pharmaceutical companies to advance the product through phase III and on to market approval. 

 

	2.	Project activities 

 Tropomyosin proteins are divided into a diverse array of isoforms. For reasons that are not
fully understood, but may relate to high turnover properties, cancer cells selectively develop a strong bias towards expression of the low molecular weight tropomyosin isoform Tpm3.1, on which they become dependent for survival. This provides a
selective target for a novel form of anti-cancer treatment. All tropomyosins first form dimers and then assemble on the actin core through head-to-tail interactions.
This interaction domain is a site of vulnerability that we will target by drug interference. Professor William Lehman (Boston University) is a world expert in the ultrastructure of the actin-tropomyosin polymer and will use combinations of protein
structure research (e.g. X-ray crystallography) and computer-aided molecular analysis to develop a sophisticated model of the target site. Our Novogen chemistry experts will design libraries of organic
molecules predicted to fit the target site and disrupt its normal function. These libraries will enter a screening cascade that begins with basic cell culture screens to determine the relative potential efficacy of each compound. At UNSW, high
throughput screening and high-content microscopy systems will be used to test; (1) compound potency against multiple independent adult cancer cell lines, (2) on-target impact on microfilament
depolymerisation using detection of actin filaments and computer-aided analysis, (3) potency of synergistic effects with a variety of pre-existing anti-cancer drugs to determine the potential utility of
combination therapy and the potential to overcome resistance mechanisms. Flexible investigative studies will also be conducted to determine the binding dynamics and specificity of the compounds using functional biochemistry in cell-free systems. A
selection of the top performing compounds will be submitted for in vitro predictive absorption, distribution, metabolism, excretion and toxicology (ADMET) analysis. All of these data will be collated for quantitative structure activity relationship
(QSAR) analysis for further rounds of modelling, drug design, synthesis and screening. These cycles will continue until the structure is maximally refined to meet the expectations of the target product profile. Overlapping studies will advance
selected lead candidates to preclinical formulation studies, efficacy testing in simple in vivo cancer models, drug delivery route analysis and maximum tolerated dosage analysis (at ICP Firefly). More sophisticated analyses of effects on tumour
growth and metastasis will follow, using specialised cell lines that allow whole body imaging of cancer progression and animal cancer models that are based on patient-derived explants and orthotopic tumour development. During the final stage, a lead
drug product will be selected from the top performing compounds and manufactured to GLP standards to undergo the battery of in vivo toxicity compliance testing necessary to support an IND application to the FDA. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 43	 

	3.	Milestones (clause 1 and 3.1) 

  

							
	 No.
	  	 Milestone
	  	 Start Date
	  	 End Date

				
	1.	  	Project Milestone Title	  	1st March 2017	  	31st August 2018
		  	Anti-tropomyosin compound libraries designed and synthesized.	  	  
		  	  
 Description
	  	  
		  	 By end date: a broad library of molecules that bind to tropomyosin 3.1 with specificity and the ability to disrupt its function in cells will
be completed. The process is cyclical—feedback from the parallel in vitro screens (Milestone 2) will improve modelling and design, allowing refinement of the activity and pharmaceutical properties.

 
 Methods: Protein structural research and computer-aided modelling (Boston University)
will dictate design of the new chemical entities (Novogen chemists), which will be manufactured by contract chemists with a strong existing Novogen relationship (GVK Hyderabad).
	  	  
				
	2.	  	Project Milestone Title	  	1st March 2017	  	28th February 2019
		  	Compound library in vitro screens completed	  	  
		  	  
 Description
	  	  
		  	 By end date: a set of lead candidate compounds (5-10) from within the chemical library generated
(Milestone 1) will have been selected, that have the most favourable (1) specificity (2) potency (3) synergy (4) pharmaceutic properties, with respect to the target product profile. This will permit advancement to the in vivo screens
(Milestone 3).
  
 Methods: High-content screens using cultured cancer cell lines (UNSW)
will be used to assess impact of drugs on actin microfilaments, cell killing potency and synergy with pre-existing anti-cancer drugs. Cell-free systems will be used to assess protein binding dynamics and
specificity (UNSW). A subset of the better-performing compounds will be screened for drug-like properties such as solubility, absorption, metabolism and cell toxicity (GVK Hyderabad).
	  	  

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 44	 

							
				
	3.	  	Project Milestone Title	  	1st March 2018	  	28th February 2019
		  	In vivo screens of lead candidates completed and single lead compound selected	  	  
		  	  
 Description
	  	  
		  	 By end date: a single lead compound from the (5-10) lead candidate molecules will have been selected
based on detailed evidence of compound efficacy in rodent models of cancer and the study of compound side-effects and pharmacokinetics in animals.
  

Methods: Mice with engrafted cancer cell lines or patient-derived tumours will be treated with lead candidates either alone or in combination with synergising
compounds identified in the in vitro screens (I C P - Firefly). Delivery routes, behaviour (pharmacokinetics) of the drugs and potential toxicities will be carefully monitored in rodents (I C P - Firefly). Some detailed analyses will investigate the
biology of compound impact using more sophisticated analytical techniques (UNSW). A variety of in vitro and vivo techniques will explore the mechanisms of action for synergism, the types of cancer that are most susceptible to the novel therapy and
the response of cell lines that are resistant to other forms of treatment, in order to develop a detailed strategy for entry into clinical trials and beyond (UNSW & Others).
	  	  
				
	4.	  	Project Milestone Title	  	1st March 2019	  	29th February 2020
		  	IND-enabling studies completed in readiness for clinical trials	  	  
		  	  
 Description
	  	  
		  	 By end date: all of the regulatory compliance studies required by the FDA for investigational new drug (IND) application will have been
completed in order to begin progression to clinical trials.
  
 Methods: The lead
compound will be manufactured to GLP standard for use in a battery of QA in vitro and in vivo tests, plus information on drug formulation, delivery route (preferably oral) and pharmacokinetic performance. Most tests performed by I C P - Firefly but
some specialist tests (e.g. cardiotoxicity and genotoxicity) performed at overseas centres.
	  	  

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 45	 

							
				
	5.	  	Project Milestone Title	  	1st March 2017	  	29th February 2020
		  	CRC-P students enrolled and CRC-P staff employed and trained	  	  
		  	  
 Description
	  	  
		  	 By end date: 1 PhD student will have been recruited, enrolled and will have completed greater than 50% of their benchwork for award of
their degree. At least 2 honours students will either have completed their degrees or will have been recruited to the program for thesis submission in late 2020. At least 2 members of staff, funded by the
CRC-P, will have been recruited to the program and trained to perform their required function within the project.
  

Methods: Search for recruitment of a competent PhD student will begin on the start date.

Supervision will be by members of the in-kind CRC-P team at UNSW and Novogen,
and internal UNSW PhD review procedures will ensure adequate progress of the student. Medical research PhDs are typically 3.5-4yrs in duration. Regardless of the PhD enrolment date, Novogen will continue to
support the PhD student beyond the life of the grant until thesis submission. Two honours students will be recruited sequentially to avoid overcommitment to teaching. The honours period of study is usually March-October of each year, which precludes
the possibility of recruitment in 2017. Ideally, the first honours student will be in 2018 and the second in 2019. Novogen will support any enrolments that overrun the life of the grant until thesis submission. At least 2 members of staff will be
recruited to the project as soon as practicable after execution of the Funding Agreement, sited primarily at UNSW and at Novogen, and will be trained by skilled members of the existing workforce to perform their required duties.
	  		  	
				
	6.	  	Completion of the Project	  		  	29th February 2020

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 46	 

	4.	Participant Expectations of the CRC-P (clause 2(b)) 

  

			
	 Item
	  	 Product / Service / Access

		
	1.	  	Draft copies of all reports prepared by the Lead Participant as part of its obligations to the Commonwealth will be circulated to all Participants for review prior to submission and final copies will be circulated after
submission.
		
	2.	  	The Lead Participant will initially organise regular individual meetings with the Participants to organise and plan Project work. At later stages of the Project, larger meetings involving all Participants may replace or add to these
meetings.
		
	3.	  	The Lead Participant will make every effort to assist the Participants in any internal or external regulatory compliance duties that arise as a consequence of the Project, including the preparation of documentation and appearance at
any meetings or hearings.
		
	4.	  	UNSW will provide reasonable building access to nominated Lead Participant staff in order for them to perform their responsibilities at UNSW.
		
	5.	  	UNSW will provide secure access to the sections of the UNSW servers storing the Agreement Material and allow the Lead Participant to make copies of the Agreement Material generated by UNSW on an ongoing basis.
		
	6.	  	UNSW will maintain conjoint appointment status for nominated Lead Participant staff in order for them to conduct Student supervision duties at UNSW.

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 47	 

 Schedule 3 – Contributions and Budget 

 
  

	1.	Participant Contributions (clause 1, 2(a) and 3.1) 

  

																					
	 Recipient/Lead Participant:Novogen Limited
	  

						
	 Contribution type
	  	2016-17	 	  	2017-18	 	  	2018-19	 	  	2019-20	 	  	Total	 
	 Cash
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 FTE
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 FTE value
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 Non-staff
in-kind
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total value of contributions
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		
	 Participant:
	  	 	I C P - Firefly Pty Limited	 
						
	 Contribution type
	  	2016-17	 	  	2017-18	 	  	2018-19	 	  	2019-20	 	  	Total	 
	 Cash
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 FTE
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 FTE value
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 Non-staff
in-kind
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total value of contributions
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
		
	 Participant:
	  	 	University of New South Wales	 
						
	 Contribution type
	  	2016-17	 	  	2017-18	 	  	2018-19	 	  	2019-20	 	  	Total	 
	 Cash
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 FTE
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 FTE value
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 Non-staff
in-kind
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total value of contributions
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	
	 TOTAL PARTICIPANT CONTRIBUTIONS
	  

						
	 Contribution type
	  	2016-17	 	  	2017-18	 	  	2018-19	 	  	2019-20	 	  	Total	 
	 Cash
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 FTE
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 FTE value
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 Non-staff
in-kind
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total value of contributions
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 48	 

 Note: FTE = Full-Time Equivalent as it relates to staff in-kind
contributions. FTE Value is calculated by multiplying the FTE value by XXXX. 
  

	2.	Budget 

  

																					
	 Heads of expenditure
	  	2016-17	 	  	2017-18	 	  	2018-19	 	  	2019-20	 	  	Total	 
	 Employee
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 Supplier
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 Capital
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
	 Other
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total expenditure
	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 	  	 	XXXXX	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 49	 

	3.	Schedule of quarterly payments to UNSW from CRC-P account 

  

															
	 Year
	  	 Quarter
	    	Instalment
(excl. GST)	 	    	GST
component	 	    	Total
(incl. GST)	 
	 2016-17
	  	Jan-Mar (Q3)	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  	Apr-Jun (Q4)	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  		    	  
	  
	 	    	  
	  
	 	    	  
	  
	 
		  	Total for 2016-17	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  		    	  
	  
	 	    	  
	  
	 	    	  
	  
	 
					
	 2017-18
	  	Jul-Sep (Q1)	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  	Oct-Dec (Q2)	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  	Jan-Mar (Q3)	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  	Apr-Jun (Q4)	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  		    	  
	  
	 	    	  
	  
	 	    	  
	  
	 
		  	Total for 2017-18	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  		    	  
	  
	 	    	  
	  
	 	    	  
	  
	 
					
	 2018-19
	  	Jul-Sep (Q1)	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  	Oct-Dec (Q2)	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  	Jan-Mar (Q3)	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  	Apr-Jun (Q4)	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  		    	  
	  
	 	    	  
	  
	 	    	  
	  
	 
		  	Total for 2018-19	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  		    	  
	  
	 	    	  
	  
	 	    	  
	  
	 
					
	 2019-20
	  	Jul-Sep (Q1)	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  	Oct-Dec (Q2)	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  	Jan-Mar (Q3)	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  		    	  
	  
	 	    	  
	  
	 	    	  
	  
	 
		  	Total for 2019-20	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  		    	  
	  
	 	    	  
	  
	 	    	  
	  
	 
	 Total
	  	Total for all years	    	 	XXXXX	 	    	 	XXXXX	 	    	 	XXXXX	 
		  		    	  
	  
	 	    	  
	  
	 	    	  
	  
	 

 Note: These payments are intended as the regular reserve to support ongoing salary payments, student stipends, materials,
consumables and all other regular costs and are made to allow UNSW to know future income and make budget projections. Additional payments and adjustments can be made for additional items or specific
sub-projects by the development of separate Work Orders (Clause 3.3) through negotiation with the Lead Participant. 
  

	4.	Payments to I C P Firefly 

 Given the nature of the work planned by I C P Firefly, which is divided into a
series of individual sub-projects, each sub-project will be negotiated, itemized, costed and set out in individual agreements as Work Orders in accordance with clause
3.3 and clause 5.4. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 50	 

 Schedule 4 – Services 

 
 PART A - Lead Participant Services 

 

			
	 Service
	  	 Applicable service standard (if any)

	In-kind contributions, staff and non-staff, according to Schedule 3	  	To a quantity and quality commensurate with monetary value (Schedule 3) and reasonable expectations for fulfilment of the Project according to Budget, Milestones and other service standards (Schedule 4).
		
	Protein modelling, molecular design and design of chemical synthesis strategy	  	Acceptable for Composition of Matter patent applications
		
	Under subcontract: modelling and molecular design verification and analysis at Boston University	  	Acceptable for publication in peer reviewed journals
		
	Under subcontract: compound synthesis, initial cytotoxicity screening and shipping to other participants	  	R&D grade compounds for all in vitro and early preclinical in vivo experiments. GLP grade for all IND-enabling in vivo studies.
		
	Screening and purchase of commercial compounds and shipping to participants	  	
		
	Under subcontract: X-Ray crystallography and other molecular analyses of tropomyosin dimer N-terminus at Boston University	  	Acceptable for publication in peer reviewed journals
		
	Under subcontract: In vitro pharmaceutic property analyses to determine drug-like characteristics.	  	Where required, to a standard that is recognised by the International Conference on Harmonisation
		
	CRC-P subcontracting, alliance management, administration, accounting, reporting, project management, communications and patent applications.	  	
		
	Collaborative contribution to student and CRC-P staff supervision at UNSW and manuscript preparation for publication	  	Acceptable to UNSW internal standards, Commonwealth expectations under the Funding Agreement and scientific journal peer-review process
		
	Any other matters relating to compound design, manufacture and Utilisation or responsibilities that would reasonably be expected from the Lead Participant of the CRC-P.	  	

 PART B - UNSW Services 
  

			
	 Service
	  	 Applicable service standard (if any)

	In-kind contributions, staff and non-staff, according to Schedule 3	  	To a quantity and quality commensurate with monetary value (Schedule 3) and reasonable expectations for fulfilment of the Project according to Budget, Milestones and other service standards (Schedule 4).

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 51	 

			
	 As required by Lead Participant according to Project goals;
  

(1)    cell culture, cell biology, microscopy and in vitro compound screening using a variety of
cell lines to determine potency, structure-activity relationship data, specificity, synergy, mechanism of action, method of cell death, biomarkers and any other cell-based methods required to determine likelihood of compound utility as an
anti-cancer agent.
  

(2)    biochemistry and molecular biology experiments using a variety of existing and developed
assays to determine binding, specificity, mechanism of action, impact on actin-tropomyosin copolymer.
  

(3)    further supporting in vitro and biochemical experiments to determine proof of concept of
anti-tropomyosin technology such as analysis of tropomyosin expression and selective isoform inhibition.
	  	To a standard acceptable for journal publication, patent application, Commonwealth reporting and, when requested by the Lead Participant for the purposes of regulatory authority submissions, to a standard that is recognised by the
International Conference on Harmonisation
		
	Preparation of reports to be submitted to regulatory bodies including the Therapeutic Goods Administration and US Food and Drug Administration with respect to experiments conducted by UNSW	  	Reports must be provided if and when requested by Lead Participant, and must be to a standard that is recognised by the International Conference on Harmonisation
		
	Primary responsibility to student and CRC-P staff supervision at UNSW and collaborative contribution to manuscript preparation for publication	  	Acceptable to UNSW internal standards, Commonwealth expectations under the Funding Agreement and scientific journal peer-review process
		
	Any other services relating to in vitro analysis of the impact of the novel anti-tropomyosin compounds on biological systems or responsibilities that would reasonably be expected from UNSW according to Project goals and the
cooperative aims of the CRC-P.	  	To a standard acceptable for journal publication, patent application, Commonwealth reporting and, when requested by the Lead Participant for the purposes of regulatory authority submissions, to a standard that is recognised by the
International Conference on Harmonisation

 PART C - ICP Firefly Services 
  

			
	 Service
	  	 Applicable service standard (if any)

	In-kind contributions, staff and non-staff, according to Schedule 3	  	To a quantity and quality commensurate with monetary value (Schedule 3) and fulfilment of the Project according to Budget, Milestones and service standards (Schedule 4).

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 52	 

			
	 As required by Lead Participant according to Project goals and prepared in consultation with ICP Firefly as individual Work Orders;

 
 (1)    experiments that
determine compound efficacy against engrafted tumours in animal models of human cancer
  

(2)    experiments that determine the maximum tolerated dose, pharmacokinetics, optimal route of
delivery and formulation, absorption, metabolism and excretion of compounds and any other drug-like characteristics
  

(3)    experiments that investigate the nature of compound toxicities in animals
	  	To a standard acceptable for journal publication, patent application, Commonwealth reporting and, for the purposes of regulatory authority submissions, to a standard that is recognised by the International Conference on
Harmonisation
		
	 As required by Lead Participant according to Project goals for Investigational New Drug-enabling studies and prepared in consultation with
ICP Firefly as individual Work Orders;
 formal studies on animals, using Good Laboratory Practice grade compounds, that are required by the Therapeutic
Goods Administration and US Food and Drug Administration in order to understand the potential toxicities of candidate molecules in future clinical trials
	  	For the purposes of regulatory authority submissions, to a standard that is recognised by the International Conference on Harmonisation
		
	Preparation of reports to be submitted to regulatory bodies including the Therapeutic Goods Administration and US Food and Drug Administration with respect to experiments conducted by ICP Firefly	  	Reports must be provided if and when requested by Lead Participant, and must be to a standard that is recognised by the International Conference on Harmonisation
		
	Any other services relating to in vivo analysis of the novel anti-tropomyosin compounds or responsibilities that would reasonably be expected from ICP Firefly according to Project goals and the cooperative aims of the CRC-P.	  	To a standard acceptable for journal publication, patent application, Commonwealth reporting and, when requested by the Lead Participant for the purposes of regulatory authority submissions, to a standard that is recognised by the
International Conference on Harmonisation

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 53	 

 Schedule 5 – Intellectual Property, Agreement Material and Utilisation 

 
  

	1.	Intellectual Property Rights and Agreement Material 

  

	 	1.1.	Ownership of Novogen Material 

  

	 	(a)	Subject to the acknowledgement in clause 4.2, all Novogen Material, and all Intellectual Property Rights in such material, will vest automatically upon its creation in the Lead Participant, and each Project Partner
presently assign to the Lead Participant all Intellectual Property Rights contained in the Novogen Materials. Each Project Partner agrees to execute or procure the execution by its Personnel of any documents reasonably necessary to give effect to
this assignment, at the Lead Participant’s expense. 

  

	 	(b)	Each Project Partner must promptly disclose and communicate in writing to the Lead Participant full particulars of any Intellectual Property Rights that the Project Partner or its Personnel make, discover or conceive in
the course of the Project that is directly related to the Novogen Materials. 

  

	 	1.2.	Ownership of Technical Assay Material 

  

	 	(c)	Subject to the acknowledgement in clause 4.2, all Technical Assay Material, and all Intellectual Property Rights in such material, will vest automatically upon its creation in UNSW, and each of ICP Firefly and the Lead
Participant presently assign to UNSW all Intellectual Property Rights contained in the Technical Assay Material. Each of ICP Firefly and the Lead Participant agrees to execute or procure the execution by its Personnel of any documents reasonably
necessary to give effect to this assignment, at UNSW’s expense. 

  

	 	(d)	Each of ICP Firefly and the Lead Participant must promptly disclose and communicate in writing to UNSW full particulars of any Intellectual Property Rights that the relevant Party or its Personnel make, discover or
conceive in the course of the Project that is directly related to the Technical Assay Materials. 

  

	 	1.3.	Pre-Existing Material 

 In order to carry out
the Project and Utilise the Agreement Material, the Participants may use Intellectual Property Rights which are part of the Participant’s Pre-existing Material. Any such
Pre-existing Material remains the sole property of the relevant Participant. 
  

	 	1.4.	Licences 

  

	 	(a)	The Lead Participant grants to each Project Partner and its Personnel a non-exclusive, royalty free, licence to use the Pre-existing
Material of the Lead Participant which has been provided by or on behalf of the Lead Participant for use in the Project, and the Novogen Materials solely to the extent required to carry out the Project and perform this Agreement. 

 

	 	(b)	Each Project Partner grants to the Lead Participant a non-exclusive, perpetual, irrevocable, worldwide, royalty free licence to use (including the right to sub-licence) the
Project Partner’s Pre-existing Material which has been provided by or on behalf of that Project Partner for use in the Project, solely for the purpose of the Project and the Utilisation of the Novogen
Materials. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 54	 

	 	(c)	Each Project Partner grants to the other Project Partner a non-exclusive, royalty free licence to use (including the right to sub-licence)
the Project Partner’s Pre-existing Material which has been provided by or on behalf of that Project Partner for use in the Project, solely for the purpose of the Project. 

 

	 	(d)	UNSW grants: 

  

	 	(i)	to each of ICP Firefly and the Lead Participant and their Personnel a non-exclusive, royalty free, licence to use the Technical Assay Materials solely to the extent required to
carry out the Project and perform this Agreement. 

  

	 	(ii)	the licence to the Commonwealth set out in clause 4.1 of this Agreement. 

  

	 	(e)	Except for the licences described in this Schedule 5, no Participant nor any of its Personnel acquires any right or interest in any Pre-existing Material provided by or on
behalf of any other Participant. 

  

	2.	Utilisation 

  

	2.1	Utilisation 

 Subject to any licence granted to the Commonwealth or another Party under
this Agreement or the Funding Agreement: 
  

	 	(a)	The Lead Participant will be solely entitled to Utilise all Novogen Material, and all Intellectual Property Rights in such material, and resulting Intellectual Property Rights, developments, and any commercial gains
that arise from that Utilisation shall be exclusively the property of the Lead Participant. 

  

	 	(b)	UNSW will be solely entitled to Utilise the Technical Assay Material, and all Intellectual Property Rights in such material, and all resulting Intellectual Property Rights, developments, and any commercial gains that
arise from that Utilisation shall be exclusively the property of UNSW. 

  

	2.2	Cooperation 

 Each Project Partner must cooperate with the Lead Participant and promptly
do all acts and things and execute all documents which may be necessary for the purpose of vesting ownership of the legal and beneficial interest in the Agreement Material, and all Intellectual Property Rights in such material, as required under
this Agreement. 
  

	2.3	Protection Actions - Novogen Material 

  

	 	(a)	The Lead Participant will be responsible for, in the Lead Participant’s absolute discretion, procuring and maintaining any registrations, listing or other rights deemed reasonably appropriate by Lead Participant
for the protection of the Novogen Material, and all Intellectual Property Rights in such material, including: 

  

	 	(i)	filing and prosecuting any applications for registration; 

  

	 	(ii)	maintaining any registrations that issue from such applications; 

  

	 	(iii)	paying all applicable fees for such applications and registrations; 

  

	 	(iv)	abandoning any applications for registration; and 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 55	 

	 	(v)	deciding whether to maintain any registrations that issue from such applications, 

 (each a
Protection Action). 
  

	 	(b)	Each Participant must provide all reasonable assistance necessary for the Lead Participant to undertake a Protection Action, at the Lead Participant’s expense. 

 

	 	(c)	Any costs associated with the Lead Participant undertaking any Protection Action will be borne solely by the Lead Participant. 

  

	2.4	Protection Actions - Technical Assay Material 

  

	 	(a)	UNSW will be responsible for, in UNSW’s absolute discretion, procuring and maintaining any registrations, listing or other rights deemed reasonably appropriate by UNSW for the protection of the Technical Assay
Material, and all Intellectual Property Rights in such material, including: 

  

	 	(i)	filing and prosecuting any applications for registration; 

  

	 	(ii)	maintaining any registrations that issue from such applications; 

  

	 	(iii)	paying all applicable fees for such applications and registrations; 

  

	 	(iv)	abandoning any applications for registration; and 

  

	 	(v)	deciding whether to maintain any registrations that issue from such applications, 

 (each a
UNSW Protection Action). 
  

	 	(b)	Each Participant must provide all reasonable assistance necessary for UNSW to undertake a UNSW Protection Action, at UNSW’s expense. 

 

	 	(c)	Any costs associated with UNSW undertaking any UNSW Protection Action will be borne solely by UNSW. 

  

	2.5	Infringement 

  

	 	(a)	Each Party must promptly and fully inform the other Party of: 

  

	 	(i)	any infringement or threatened infringement; 

  

	 	(ii)	any unauthorised use of or application; or 

  

	 	(iii)	any challenge or threatened challenge on the grant or validity, 

 of the Intellectual Property
Rights or title (or any aspect thereof) in the Pre-existing Material, Agreement Material, including the Technical Assay Material, or which comes to that Party’s attention (each an Infringement).

  

	 	(b)	Where a Participant reasonably suspects that an Infringement has occurred, the Participant may request any other Participant or Participants to provide information and
non-financial assistance as is reasonably necessary to assist in determining whether or not an Infringement has occurred. 

  

	 	(c)	For the avoidance of doubt, nothing in this item 2.5 will be taken as requiring a Participant to expend funds in relation to litigation or the protection of another Participant’s Intellectual Property Rights.

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 56	 

	3.	Warranty 

  

	 	(a)	Each Participant represents and warrants to the other Participants that: 

  

	 	(i)	at the date it makes Pre-existing Materials available to the Project, to its actual knowledge and belief, without the need to make additional enquiries, conduct searches or seek
legal or patent opinion, it is the owner of, or is otherwise entitled to provide, Participant’s Pre-existing Materials which it makes available for the Project; and 

 

	 	(ii)	except to the extent notified in writing to the other Participants at the time of providing the Participant’s Pre-existing Materials neither the Participant, nor its
Personnel, research fellows or students (if applicable) have entered into any agreement regarding, or have otherwise dealt with, the Participant’s Pre-existing Materials in a manner that is inconsistent
with, or restricts the exercise of the rights granted to, other Participants under this Agreement. 

  

	4.	Survival 

 This Schedule 5 survives termination or expiration of this Agreement. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 57	 

 Schedule 6 – Privacy Obligations with respect to information received from the Commonwealth 

 
  

	1.1	Obligations 

  

	 	(a)	Each Participant agrees in respect of the Project under this Agreement to take all necessary measures to ensure that personal information in its possession or control in connection with this Agreement is protected
against loss and unauthorised access, use, disclosure or modification. 

  

	 	(b)	Each Participant must, when requested, provide to the Commonwealth through the Lead Participant: 

  

	 	(i)	a copy of the Participant’s APP privacy policy which is compliant with APP 1; 

  

	 	(ii)	copies of the Participant’s security and data protection policies; and 

  

	 	(iii)	details of the Participant’s processes and procedures implemented to ensure compliance with the Privacy Act. 

  

	 	(c)	Each Participant agrees in respect of the Project under this Agreement: 

  

	 	(i)	to use or disclose personal information obtained, directly or indirectly, from the Commonwealth during the course of the Project under this Agreement, only for the purposes of this Agreement; 

 

	 	(ii)	not to do any act or engage in any practice that would breach an APP contained in schedule 1of the Privacy Act, which if done or engaged in by an agency, would be a breach of that APP; 

 

	 	(iii)	to carry out and discharge the obligations contained in the APPs as if it were an agency under the Privacy Act; 

  

	 	(iv)	to notify individuals whose personal information the Participant holds, that complaints about acts or practices of the Participant may be investigated by the Privacy Commissioner who has power to award compensation
against the Participant in appropriate circumstances; 

  

	 	(v)	not to use or disclose personal information or engage in an act or practice that would breach APP 7 (direct marketing) or a registered APP Code which is applicable to the Participant, unless the use or disclosure
is necessary, directly or indirectly, to discharge an obligation of this Agreement; 

  

	 	(vi)	to follow any reasonable directions given by the Commonwealth through the Lead Participant to ensure compliance with the Privacy Act; 

 

	 	(vii)	to not transfer or transmit personal information outside of Australia except with the prior written approval of the Commonwealth, which will not be unreasonably withheld. In giving its approval the Commonwealth may
impose such conditions as it thinks fit. The Participant must comply with any term or condition imposed by the Commonwealth under this item 1.1(c)(vii); 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 58	 

	 	(viii)	to disclose in writing to any person who asks, the content of the provisions of this Agreement (if any) that are inconsistent with an APP or a registered APP Code which is binding on a party to this Agreement;

  

	 	(ix)	to immediately notify the Commonwealth through the Lead Participant if the Participant becomes aware of a breach or possible breach of any of the obligations contained in, or referred to in, this Schedule 6,
whether by the Participant or any of its Personnel (including any complaints made about acts or practices of the Participant in connection with personal information); 

 

	 	(x)	to notify the Commonwealth through the Lead Participant of any subpoena, warrant, order, demand or request made by a foreign court or other authority for the disclosure of personal information to which the Privacy Act
applies and to not disclose such information without the prior written approval of the Commonwealth, which will not be unreasonably withheld. In giving its approval the Commonwealth may impose such conditions as it thinks fit. The Participant must
comply with any term or condition imposed by the Commonwealth under this item 1.1(c)(x); 

  

	 	(xi)	to comply with any directions, guidelines, determinations or recommendations of the Privacy Commissioner, notified to the Participant by the Commonwealth to the extent that they are not inconsistent with the
requirements of this Schedule 6; and 

  

	 	(xii)	to ensure that any Personnel of the Participant who is required to deal with personal information for the purposes of this Agreement is made aware of the obligations of the Participant as set out in this
Schedule 6. 

  

	1.2	Indemnity 

 The Project Participants agree to indemnify the Commonwealth in respect of
any loss or liability suffered or incurred by the Commonwealth which arises directly or indirectly from a breach of any of the obligations of the Agreement under this Schedule 6. 

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 59	 

 Signing page 

 
  

							
	Executed by Novogen Limited in accordance with section 127 of the Corporations Act 2001 (Cth) in the presence of	  		  		  	
				
	  
	  	f	  	  
	  	f
	Signature of director	  		  	 Signature of director/company secretary/sole director and sole company secretary

(Please delete as applicable)
	  	
				
	  
	  		  	  
	  	
	Name of director (print)	  		  	Name of director/company secretary/sole director and sole company secretary (print)	  	
				
	Signed for and on behalf of the University of New South Wales by an authorised officer in the presence of	  		  		  	
				
	  
	  	f	  	  
	  	f
	Signature of witness	  		  	Signature of officer	  	
				
	  
	  		  	  
	  	
	Name of witness (print)	  		  	Name of officer (print)	  	
				
		  		  	  
	  	
		  		  	Office held	  	

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 60	 

							
	Executed by ICP - Firefly Pty. Limited in accordance with section 127 of the Corporations Act 2001 (Cth) in the presence of	  		  		  	
				
	  
	  	f	  	  
	  	f
	Signature of director	  		  	 Signature of director/company secretary/sole director and sole company secretary

(Please delete as applicable)
	  	
				
	  
	  		  	  
	  	
	Name of director (print)	  		  	Name of director/company secretary/sole director and sole company secretary (print)	  	

  
 Confidential material
omitted and filed separately with the Commission. 

  

					
	Participants Agreement | CRC Project | Targeting Tropomyosin as a Novel Anti-Cancer Therapy	  	 	Page 61EX-4.15

 Exhibit 4.15 

EMPLOYMENT AGREEMENT 

This Executive Employment Agreement (“Agreement”) dated as of September 1, 2016 (the “Effective Date”),
is between Novogen North America, Inc., (the “Company”) and Dr. Peng Leong (“Executive”). 

WHEREAS, the Company desires to employ Executive as its Chief Business Officer; and 

WHEREAS, the Company and Executive desire to enter into this Agreement as to the terms of Executive’s employment with the Company.

 NOW, THEREFORE, in consideration of the foregoing, of the mutual promises contained herein and of other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 
 1. POSITION
AND DUTIES. 
 (a) During the Employment Term (as defined in Section 2 hereof), Executive shall serve as the Chief Business Officer
and will report to the CEO of Novogen, Ltd. In this capacity, Executive shall have the duties, authorities and responsibilities as shall be determined by the CEO from time to time. In Executive’s role as Chief Business Officer, Executive shall
be responsible for in-licensing and out-licensing of development candidates in Novogen’s portfolio, driving corporate strategy, and advising on fund-raising and
financing activities. Executive’s position shall initially be based in Boston, Massachusetts. 
 (b) During the Employment Term,
Executive shall devote all of Executive’s business time, energy, business judgment, knowledge and skill and Executive’s best efforts to the performance of Executive’s duties with the Company; provided that the foregoing shall
not prevent Executive from (i) serving on the boards of directors of non-profit organizations, (ii) participating in charitable, civic, educational, professional, community or industry affairs, and
(iii) managing Executive’s passive personal investments so long as such activities, individually or in the aggregate, do not interfere or conflict with Executive’s duties hereunder or create a potential business or fiduciary conflict.

 2. EMPLOYMENT TERM. The Company agrees to employ Executive pursuant to the terms of this Agreement, and Executive
agrees to be so employed for a term commencing as of Effective Date and continuing until Executive’s employment is terminated in accordance with Section 6 hereof. The period of time between the Effective Date and the termination of
Executive’s employment hereunder shall be referred to herein as the “Employment Term.” 
 3. BASE
SALARY. The Company agrees to pay Executive a base salary at an initial annual rate of three hundred thousand dollars and zero cents ($300,000.00), paid semi-monthly in accordance with the regular payroll practices of the Company.
Executive’s Base Salary shall be subject to annual review by the Board (or a committee thereof), and may be increased, but not decreased, from time to time in the sole discretion of the Board. The base salary as determined herein and as
adjusted upwards from time to time shall constitute “Base Salary” for purposes of this Agreement. 

  
 1 

 4. BONUSES 

(a) Annual Bonus. During the Employment Term, Executive shall be eligible to receive an annual discretionary incentive payment under the
Company’s annual bonus plan as may be in effect from time to time (the “Annual Bonus”) based on a target bonus opportunity of 15% of Executive’s Base Salary upon the attainment of one or more
pre-established performance goals. This bonus is payable during the following calendar year as determined by the Company only when those specific goals are met. Executive shall not be entitled to the Annual
Bonus (or any portion thereof) if the Executive is not employed with the Company on the date the Annual Bonus is otherwise to be paid to Executive. Executive shall not be entitled to an Annual Bonus for calendar year 2016. 

(b) Signing Bonus. Executive shall receive a Signing Bonus of $50,000, less applicable withholdings and deductions, on the next
regularly scheduled payroll subsequent to the Effective Date of this Agreement. Should Executive elect to leave the Company for any reason within the first twelve (12) months of his employment, Executive’s Signing Bonus shall be repayable
to the Company in full immediately upon his departure. 
 (c) Annual Stipend. During the Employment Term, Executive shall receive an
Annual Stipend of twenty-six thousand dollars and zero cents ($26,000.00) to use at his discretion, payable in twelve equal installments on the first payroll cycle of each month during a calendar year.
Executive shall be paid the pro rata amount of the Annual Stipend for calendar year 2016. The monthly Annual Stipend payments do not accrue or vest and shall immediately cease upon Executive’s termination. 

5. EMPLOYEE BENEFITS. 

(a) [[STOCK OPTIONS. Executive shall be eligible to receive options over the common stock of the Company as follows: 

 

	 	(i)	2,000,000 options, priced at a 55% premium to the 7-day VWAP at time of engagement, vesting in four equal annual tranches after one, two, three and four years of service;

  

	 	(ii)	500,000 additional options in the event of a successful execution of the in-licensing transaction known as ‘Project Rubicon,’ provided Executive commences employment on
or before September 5, 2016. 

  

	 	(iii)	750,000 additional options in the event of subsequent in-licensing or out-licensing transactions, to a maximum of 1,500,000 options,
provided that the total value of upfront and milestone payments of each transaction exceeds $1 Million USD. 

 The
strike price of the options referenced in Section 5(b)(ii) and (iii) will be set at a 55% premium to the 7-day VWAP prior to announcement of the respective transaction and the options awarded will
vest in three equal tranches after one, two and three years of service. The options described herein will be subject to the terms and conditions of the Company’s equity incentive plan. The Company’s securities are listed on the Australian Securities Exchange under the ticker ‘NRT.’ 
 (b)
VACATIONS, SICK DAYS AND HOLIDAYS. During the Employment Term, Executive shall be entitled to a certain number of paid vacation and sick days in accordance with the Company’s vacation and sick leave policies applicable to employees as in
effect from time to time; provided that Executive shall be entitled to not less than 20 days paid vacation and 6 paid sick days each calendar year during the Employment Term. All accrued but unused vacation shall be paid to Executive upon
termination of this Agreement. All accrued but unused sick pay shall forfeited upon termination of this Agreement. Executive shall be paid for the following Holidays: New Year’s Day, Memorial Day, Independence Day, Labor Day, Thanksgiving Day
and Christmas Day. 

  
 2 

 (c) BUSINESS EXPENSES. Upon presentation of reasonable substantiation and
documentation as the Company may specify from time to time, Executive shall be reimbursed in accordance with the Company’s expense reimbursement policy provided to Executive in writing, for all ordinary and reasonable out-of-pocket business expenses incurred and paid by Executive during the Employment Term and in connection with the performance of Executive’s duties hereunder, in
accordance with the Company’s policies with regard thereto.  
 6. TERMINATION. Executive’s employment and
the Employment Term shall terminate on the first of the following to occur: 
 (a) DISABILITY. Upon ten (10) days’ prior
written notice by the Company to Executive of termination due to Disability. For purposes of this Agreement, “Disability” shall mean the inability of Executive to have performed Executive’s material duties hereunder due to a
physical or mental injury, infirmity or incapacity for one hundred twenty (120) days (including weekends and holidays) in any 365-day period, as determined by a qualified medical doctor acceptable to the
Board. Executive shall cooperate in all reasonable respects with the Company if a question arises as to whether Executive has become disabled (including, without limitation, submitting to reasonable examinations by one or more medical doctors and
other health care specialists selected by the Company and authorizing such medical doctors and other health care specialists to discuss Executive’s condition with the Company). 

(b) DEATH. Automatically upon the date of death of Executive. 

(c) CAUSE. Immediately upon written notice by the Company to Executive of a termination for Cause. “Cause”
shall mean: 
 (i) Executive’s willful, material misconduct or gross negligence in the performance of Executive’s duties; 

(ii) Executive’s willful failure to follow the lawful directives of the Board, but only after the Board provides Executive with
reasonable written notice and an opportunity to cure; 
 (iii) Executive’s conviction of, or pleading of guilty or nolo
contendere to, a felony or any crime involving moral turpitude; 
 (iv) Executive’s performance of any material act of theft,
embezzlement, fraud, malfeasance, dishonesty or misappropriation with respect to the Company’s property; or 
 (v) Executive’s
material breach of this Agreement, or any other material written agreement with the Company, or other material written policy with reasonable written notice and an opportunity to cure. 

(d) WITHOUT CAUSE. Immediately upon written notice by the Company to Executive of an involuntary termination without Cause (other than
for death or Disability). 
 (e) BY EXECUTIVE. Upon ninety (90) days’ prior written notice by Executive to the Company of
Executive’s voluntary termination of employment for any reason other than Good Reason (which the Company may, in its sole discretion, make effective earlier than any notice date). 

  
 3 

 (f) BY EXECUTIVE FOR GOOD REASON. Executive’s termination will be for “Good
Reason” if Executive provides written notice to the Company of the Good Reason within ninety (90) days of the event constituting Good Reason, and only with respect to clauses (i), (iv) and (v) of this subsection, provides the Company
with a period of thirty (30) days to cure the Good Reason and the Company fails to cure the Good Reason within that period. In such event Executive may terminate his employment for Good Reason, in which case Executive will be eligible to
receive Severance Pay in accordance with the terms and conditions set forth in Section 7(d) below. In no event will a termination be considered for Good Reason if the termination date is more than six (6) months following the initial
existence of the condition constituting Good Reason. 
 For purposes of this Agreement, “Good Reason” means any of the
following events if the event is effected by the Company without the consent of Executive: (i) a material reduction in Executive’s authority, level of responsibility, policy making functions, or duties, other than changes affecting all
similarly situated employees within the Company; (ii) any reduction in Executive’s Base Salary; (iii) any reduction in Executive’s bonus opportunity, other than changes affecting all similarly situated employees within the
Company; (iv) a breach by the Company of any material provision of this Agreement or any other agreement between Executive and the Company. 

7. CONSEQUENCES OF TERMINATION. 

(a) DEATH. In the event that Executive’s employment and the Employment Term end on account of Executive’s death,
Executive or Executive’s estate, as the case may be, shall be entitled to the following (with the amounts due under Sections 7(a)(i) through 7(a)(iii) hereof to be paid within sixty (60) days following termination of employment, or such
earlier date as may be required by applicable law): 
 (i) any earned and unpaid Base Salary through the date of termination; 

(ii) reimbursement for any unreimbursed business expenses incurred through the date of termination; 

(iii) any accrued but unused vacation time in accordance with Company policy; and 

(iv) all other accrued and vested payments, benefits or fringe benefits to which Executive shall be entitled under the terms of any applicable
compensation arrangement or benefit, equity or fringe benefit plan or program or grant, in each case in accordance with their terms, including timing of payment hereof, shall be hereafter referred to as the “Accrued Benefits”). 

(b) DISABILITY. In the event that Executive’s employment and/or Employment Term ends on account of Executive’s Disability,
the Company shall pay or provide Executive with the Accrued Benefits. 
 (c) TERMINATION FOR CAUSE OR BY EXECUTIVE. If
Executive’s employment is terminated (x) by the Company for Cause, or (y) by Executive for any reason other than for Good Reason, the Company shall pay to Executive the Accrued Benefits. 

  
 4 

 (d) TERMINATION WITHOUT CAUSE OR FOR GOOD REASON. If Executive’s employment by
the Company is terminated by the Company other than for Cause, Death or Disability, or if Executive’s employment is terminated by Executive for Good Reason, the Company shall pay or provide Executive with the following, subject to the
provisions of Section 21 hereof: 
 (i) the Accrued Benefits; and 

(ii) subject to Executive’s continued compliance with the obligations in Sections 8, 9 and 10 hereof, an aggregate amount equal to three
(3) months of Executive’s annual Base Salary in effect on the date of termination, paid in equal installments in accordance with the Company’s normal payroll practice for a period of three (3) months following such termination;
provided that to the extent that the payment of any amount constitutes “nonqualified deferred compensation” for purposes of Code Section 409A, any such payment scheduled to occur during the first sixty (60) days following
the termination of employment shall not be paid until the first regularly scheduled pay period following the sixtieth (60th) day following such termination and shall include payment of any amount
that was otherwise scheduled to be paid prior thereto, otherwise such payments will commence with the first payroll period following the date the release described in Section 8 becomes effective and not subject to revocation and shall include
payment of any amount that was otherwise scheduled to be paid prior thereto. 
 Payments and benefits provided in this Section 7(d)
shall be in lieu of any termination or severance payments or benefits for which Executive may be eligible under any of the plans, policies or programs of the Company or under the Worker Adjustment Retraining Notification Act of 1988 or any similar
state statute or regulation. 
 (e) OTHER OBLIGATIONS. Upon any termination of Executive’s employment with the Company,
Executive shall be deemed to have immediately resigned from any position as an officer, director or fiduciary of any Company-related entity. Following any termination of employment, Executive will reasonably cooperate with the Company in the winding
up of pending work on behalf of the Company and the orderly transfer of work to other employees. Executive will also reasonably cooperate with the Company (at the Company’s expense) in the defense of any action brought by any third party
against the Company that relates to Executive’s employment by the Company. 
 (f) EXCLUSIVE REMEDY. The amounts payable to
Executive following termination of employment and the Employment Term hereunder pursuant to Section 7 hereof shall be in full and complete satisfaction of Executive’s rights under this Agreement and any other claims that Executive
may have in respect of Executive’s employment with the Company or any of its affiliates. 
 8. RELEASE. Any and
all amounts payable and benefits or additional rights provided pursuant to this Agreement beyond the Accrued Benefits (which shall not be subject to the release hereinafter described) shall only be payable if Executive delivers to the Company and
does not revoke a general release of claims in favor of the Company in a form reasonably satisfactory to the Company; provided that Executive’s rights to or ownership in any equity in the Company or its affiliates or rights to indemnification
and directors and officers liability insurance protection under the Company’s governing documents or contract shall not be released. Such release shall be executed and delivered (and no longer subject to revocation, if applicable) within sixty
(60) days following termination. 

  
 5 

 9. RESTRICTIVE COVENANTS. 

(a) CONFIDENTIALITY. During the course of Executive’s employment with the Company, Executive will have access to
Confidential Information. For purposes of this Agreement, “Confidential Information” means all data, information, ideas, concepts, discoveries, trade secrets, inventions (whether or not patentable or reduced to practice), innovations,
improvements, know-how, developments, techniques, methods, processes, treatments, drawings, sketches, specifications, designs, plans, patterns, models, plans and strategies, and all other confidential or
proprietary information or trade secrets in any form or medium (whether merely remembered or embodied in a tangible or intangible form or medium) whether now or hereafter existing, relating to or arising from the past, current or potential business,
activities and/or operations of the Company or any of its affiliates (or any of their respective predecessors, successors or permitted assigns), including, without limitation, any such information relating to or concerning finances, sales,
marketing, advertising, transition, promotions, pricing, personnel, customers, suppliers, vendors, partners and/or competitors. Executive agrees that Executive shall not, directly or indirectly, use, make available, sell, disclose or otherwise
communicate to any person, other than in the course of Executive’s assigned duties and for the benefit of the Company, either during the period of Executive’s employment or at any time thereafter, any Confidential Information or other
confidential or proprietary information received from third parties subject to a duty on the Company’s and its subsidiaries’ and affiliates’ part to maintain the confidentiality of such information, and to use such information only
for certain limited purposes strictly for the benefit of the Company or any of its affiliates. 
 The terms and conditions of this Agreement
shall remain strictly confidential, and Executive hereby agrees not to disclose the terms and conditions hereof to any person or entity, other than immediate family members, legal advisors or personal tax or financial advisors, or, solely for the
purpose of disclosing the limitations on Executive’s conduct imposed by the provisions of this Section 9, prospective future employers who, in each case, agree to keep such information confidential. Notwithstanding the foregoing,
Confidential Information shall not include any information that Executive can demonstrate (i) was lawfully in Executive’s possession prior to commencing employment with the Company or any of its predecessors, successors or affiliates and
not obtained in connection with Executive’s commencement of such employment, (ii) constitutes industry knowledge or is generally available, or is made generally available, to the public other than as a result of a direct or indirect
disclosure by Executive, or (iii) becomes available to Executive on a non-confidential basis from a source other than the Company or its employees, officers, affiliates, predecessors, successors or
assigns. 
 (b) NONSOLICITATION; NONINTERFERENCE. 

(i) During Executive’s employment and service with the Company and for a period of twelve (12) months thereafter,
Executive agrees that Executive shall not, except in the furtherance of Executive’s duties hereunder, directly or indirectly, individually or on behalf of any other person, firm, corporation or other entity, solicit, aid or induce any
individual or entity that is, or was during the twelve-month period immediately prior to the termination of Executive’s employment for any reason, a customer of the Company or any of its subsidiaries or affiliates to purchase goods or services
then sold by the Company or any of its subsidiaries or affiliates from another person, firm, corporation or other entity or assist or aid any other persons or entity in identifying or soliciting any such customer. 

(ii) During Executive’s employment and service with the Company and for a period of twelve (12) months thereafter,
Executive agrees that Executive shall not, except in the furtherance of Executive’s duties hereunder, directly or indirectly, individually or on behalf of any other person, firm, corporation or other entity, (A) solicit, aid or induce any
employee, representative or agent of the Company or any of its subsidiaries or affiliates to leave such employment or retention or solicit, aid or induce any employee of the Company or any of its subsidiaries or affiliates to accept employment with
or render services to or with any other person, firm, corporation or other entity unaffiliated with the Company or hire or retain any such employee, or take any action to materially assist or aid any other person, firm, corporation or other entity
in identifying, hiring or soliciting any such employee, representative or agent, or (B) interfere, or aid or induce any other person or entity in interfering, with the relationship between the Company or any of its subsidiaries or affiliates
and any of their respective vendors, joint venturers or licensors. Any person described in this Section 9(c)(ii) shall be deemed covered by this Section while so employed or retained and for a period of twelve (12) months
thereafter. 

  
 6 

 (c) NONDISPARAGEMENT. Executive agrees not to make negative comments or otherwise
disparage the Company or any of its affiliates or any of their respective partners, members, officers, directors, employees, shareholders, agents or products. The foregoing shall not be violated by truthful statements in response to legal process,
required governmental testimony or filings, or administrative or arbitral proceedings (including, without limitation, depositions in connection with such proceedings). 

(d) INVENTIONS. Executive acknowledges and agrees that all ideas, methods, inventions, discoveries, improvements, work products,
developments or works of authorship (“Inventions”), whether patentable or unpatentable, (A) that relate to Executive’s work with the Company, made or conceived by Executive, solely or jointly with others, during the
Employment Term, or (B) suggested by any work that Executive performs in connection with the Company, either while performing Executive’s duties with the Company or on Executive’s own time, shall belong exclusively to the Company (or
its designee), whether or not patent applications are filed thereon. Executive hereby irrevocably conveys, transfers and assigns to the Company the Inventions and all patents that may issue thereon in any and all countries, whether during or
subsequent to the Employment Term, together with the right to file, in Executive’s name or in the name of the Company (or its designee), applications for patents and equivalent rights (the “Applications”). Executive will, at
any time during and subsequent to the Employment Term, and at the Company’s expense, make such applications, sign such papers, take all rightful oaths, and perform all acts as may be reasonably requested from time to time by the Company with
respect to the Inventions. Executive will also execute assignments to the Company (or its designee) of the Applications, and give the Company and its attorneys all reasonable assistance (including the giving of testimony) to obtain the Inventions
for the Company’s benefit, all without additional compensation to Executive from the Company, but entirely at the Company’s expense. If the Company is unable for any other reason to secure Executive’s signature on any document for
this purpose, then Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Executive’s agent and attorney in fact, to act for and in Executive’s behalf and stead to execute any
documents and to do all other lawfully permitted acts in connection with the foregoing. 
 In addition, the Inventions will be deemed Work
for Hire, as such term is defined under the copyright laws of the United States, on behalf of the Company and Executive agrees that the Company will be the sole owner of the Inventions, and all underlying rights therein, in all media now known or
hereinafter devised, throughout the universe and in perpetuity without any further obligations to Executive. If the Inventions, or any portion thereof, are deemed not to be Work for Hire, Executive hereby irrevocably conveys, transfers and assigns
to the Company, all rights, in all media now known or hereinafter devised, throughout the universe and in perpetuity, in and to the Inventions, including, without limitation, all of Executive’s right, title and interest in the copyrights (and
all renewals, revivals and extensions thereof) to the Inventions, including, without limitation, all rights of any kind or any nature now or hereafter recognized, including, without limitation, the unrestricted right to make modifications,
adaptations and revisions to the Inventions, to exploit and allow others to exploit the Inventions and all rights to sue at law or in equity for any infringement, or other unauthorized use or conduct in derogation of the Inventions, known or
unknown, prior to the date hereof, including, without limitation, the right to receive all proceeds and damages therefrom. In addition, Executive hereby waives any so-called “moral rights” with
respect to the Inventions. To the extent that Executive has any rights in the results and proceeds of Executive’s service to the Company that cannot be assigned in the manner described herein, Executive agrees to unconditionally waive
the enforcement of such rights. Executive hereby waives any and all currently existing and future monetary rights in and to the Inventions and all patents that may issue thereon, including, without limitation, any rights that would otherwise accrue
to Executive’s benefit by virtue of Executive being an employee of or other service provider to the Company. 
 Executive shall comply
with all relevant agreements, policies and guidelines of the Company to which Executive is actually made aware regarding the protection of confidential information and intellectual property and potential conflicts of interest, provided the same are
consistent with the terms of this Agreement and Executive’s duties to the Company and its affiliates. Executive acknowledges that the Company may amend any such policies and guidelines from time to time, and that Executive remains at all times,
on or after such revision has been published to Executive, bound by their most current version. 

  
 7 

 The provisions of this Section 9(e) shall not apply to an Invention for which no
equipment, supplies, facility, or trade secret information of the Company was used and which was developed entirely on Executive’s own time, unless (a) the invention relates (i) to the business of the Company, or (ii) to the
Company’s actual or demonstrably anticipated research or development, or (b) the Invention results from any work performed by Executive for the Company. 

(e) DISCLOSURE OF TRADE SECRETS. Executive understands that pursuant to the Defend Trade Secrets Act of 2016, he shall not be held
criminally, or civilly, liable under any Federal or State Trade secret law for the disclosure of a trade secret that is made in confidence either directly or indirectly to a Federal, State, or local government official, or an attorney, for the sole
purpose of reporting, or investigating, a violation of law. Executive further understands that employees may disclose trade secrets in a complaint, or other document, filed in a lawsuit, or other proceeding, if such filing is made under
seal. Finally, Executive understands an employee who files a lawsuit alleging retaliation by the Company for reporting a suspected violation of the law may disclose the trade secret to the attorney of the employee and use the trade secret in
the court proceeding, if the employee files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order. 

(f) REASONABLENESS OF COVENANTS. In signing this Agreement, Executive has carefully read and considered all of the terms and conditions
of this Agreement, including the restraints imposed under this Section 9. Executive agrees that these restraints are necessary for the reasonable and proper protection of the Company and its affiliates and their trade secrets and
confidential information and that each and every one of the restraints is reasonable in respect to subject matter, length of time and geographic area, and that these restraints, individually or in the aggregate, will not prevent Executive from
obtaining other suitable employment during the period in which Executive is bound by the restraints. Executive acknowledges that each of these covenants has a unique, very substantial and immeasurable value to the Company and its affiliates and that
Executive has sufficient assets and skills to provide a livelihood while such covenants remain in force. Executive further covenants that Executive will not challenge the reasonableness or enforceability of any of the covenants set forth in this
Section 9, and that Executive will reimburse the Company and its affiliates for all costs (including reasonable attorneys’ fees) incurred in connection with any action to enforce any of the provisions of this Section 9
if either the Company and/or any of its affiliates is the prevailing party in such dispute or if Executive challenges the reasonableness or enforceability of any of the provisions of this Section 9. It is also agreed that each of the
Company’s affiliates will have the right to enforce all of Executive’s obligations to that affiliate under this Agreement and shall be third party beneficiaries hereunder, including without limitation pursuant to this
Section 9. Executive acknowledges and agrees that the restrictive covenants set forth in this Agreement are independent covenants and shall be in addition to, and shall not supersede or be deemed to be in lieu of, any restrictive
covenants set forth in any other agreement between Executive and the Company or its affiliates, including, without limitation, any restrictive covenants set forth in any equity-based incentive plan or grant agreement. 

(g) REFORMATION. If it is determined by a court of competent jurisdiction in any state that any restriction in this
Section 9 is excessive in duration or scope or is unreasonable or unenforceable under applicable law, it is the intention of the parties that such restriction may be modified or amended by the court to render it enforceable to the
maximum extent permitted by the laws of that state. 
 (h) TOLLING. In the event of any violation of the provisions of this
Section 9, Executive acknowledges and agrees that the post-termination restrictions contained in this Section 9 shall be extended by a period of time equal to the period of such violation, it being the intention of the
parties hereto that the running of the applicable post-termination restriction period shall be tolled during any period of such violation. 

  
 8 

 (i) SURVIVAL OF PROVISIONS. The obligations contained in Sections 9 and 11 hereof
shall survive the termination or expiration of the Employment Term, the non-renewal of this Agreement and Executive’s employment with the Company and shall be fully enforceable thereafter. 

10. COOPERATION. Upon the receipt of reasonable notice from the Company (including outside counsel), Executive agrees
that while employed by the Company and thereafter, Executive will respond and provide information with regard to matters in which Executive has knowledge as a result of Executive’s employment with the Company, and will provide reasonable
assistance to the Company, its affiliates and their respective representatives in defense of any claims that may be made against the Company or its affiliates, and will reasonably assist the Company and its affiliates in the prosecution of any
claims that may be made by the Company or its affiliates, to the extent that such claims may relate to the period of Executive’s employment with the Company (collectively, the “Claims”), provided, however that in no event shall
Executive be required to (a) waive his U.S. constitutional rights or privileges, (b) cooperate in connection with a Claim brought by the Company against Executive or a Claim brought by Executive against the Company, or (c) disclose
confidential information of any third party which Executive is legally bound to maintain as confidential. 
 In exchange for the foregoing,
the Company agrees to reimburse Executive for all reasonable out of pocket expenses incurred by Executive in providing such cooperation including, but not limited, to mileage, air travel, hotel and food expenses along with compensation for
Executive’s time if no longer employed by the Company at a rate of $200.00 per hour; provided that no such compensation payment shall be required by the Company under this Section 10 during the Employment Term or during any period in which
severance is being paid to Executive pursuant to Section 7(d) hereof. Executive agrees to promptly inform the Board if Executive becomes aware of any lawsuits involving Claims that may be filed or threatened against the Company or its
affiliates. During the Employment Term, Executive also agrees to promptly inform the Board (to the extent that Executive is legally permitted to do so) if Executive is asked to assist in any investigation of the Company or its affiliates (or their
actions) or another party attempts to obtain information or documents from Executive (other than in connection with any litigation or other proceeding in which Executive is a
party-in-opposition) with respect to matters Executive believes in good faith to relate to any investigation of the Company or its affiliates, in each case, regardless
of whether a lawsuit or other proceeding has then been filed against the Company or its affiliates with respect to such investigation, and shall not do so unless legally required. During the pendency of any litigation or other proceeding involving
Claims, Executive shall not communicate with anyone (other than Executive’s attorneys and tax and/or financial advisors and except to the extent that Executive determines in good faith is necessary in connection with the performance of
Executive’s duties hereunder) with respect to the facts or subject matter of any pending or potential litigation or regulatory or administrative proceeding involving the Company or any of its affiliates without giving prior written notice to
the Board or the Company’s counsel. 
 11. RETURN OF COMPANY PROPERTY. On the date of Executive’s termination of
employment with the Company for any reason (or at any time prior thereto at the Company’s request), Executive shall return all Confidential Information or other property belonging to the Company or any of its affiliates (including, but not
limited to, any Company-provided laptops, computers, cell phones, wireless electronic mail devices or other equipment, or documents and property belonging to the Company). 

12. EQUITABLE RELIEF AND OTHER REMEDIES. Executive acknowledges and agrees that the Company’s remedies at law for a
breach or threatened breach of any of the provisions of Section 9 or Section 10 hereof would be inadequate and, in recognition of this fact, Executive agrees that, in the event of such a breach or threatened breach, in addition to
any remedies at law, the Company shall be entitled to obtain equitable relief in the form of specific performance, a temporary restraining order, a temporary or permanent injunction or any other equitable remedy which may then be available, without
the necessity of showing actual monetary damages or the posting of a bond or other security. In the event of a violation by Executive of Section 9 or 10 hereof, any severance or other benefits being paid or provided to Executive and/or
Executive’s dependents pursuant to this Agreement or otherwise shall immediately cease, and any severance previously paid to Executive shall be immediately repaid to the Company. 

  
 9 

 13. NO ASSIGNMENTS. This Agreement is personal to each of the parties
hereto. Except as provided in this Section 13 hereof, no party may assign or delegate any rights or obligations hereunder without first obtaining the written consent of the other party hereto. The Company may assign this Agreement to any
successor to all or substantially all of the business and/or assets of the Company. As used in this Agreement, “Company” shall mean the Company and any successor to its business and/or assets, which assumes and agrees to perform the
duties and obligations of the Company under this Agreement by operation of law or otherwise. 
 14. NOTICE. For purposes of
this Agreement, notices and all other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given (a) on the date of delivery, if delivered by hand, (b) on the date of transmission, if
delivered by confirmed facsimile or electronic mail, (c) on the first business day following the date of deposit, if delivered by guaranteed overnight delivery service, or (d) on the fourth business day following the date delivered or
mailed by United States registered or certified mail, return receipt requested, postage prepaid, addressed as follows: 
 If
to Executive: 
 Dr Peng Leong 

XXXX 

If to the Company: 

Novogen North America 

C/o Novogen Ltd 

PO Box 2333 

HORNSBY NSW 1635 

With a copy to: 

Baker & McKenzie 

300 East Randolph Street, Suite 5000 

Chicago, IL 60601 

Attention: Ryan H. Vann 
 or to
such other address as either party may have furnished to the other in writing in accordance herewith, except that notices of change of address shall be effective only upon receipt. 

15. SECTION HEADINGS; INCONSISTENCY. The section headings used in this Agreement are included solely for
convenience and shall not affect, or be used in connection with, the interpretation of this Agreement. In the event of any inconsistency between the terms of this Agreement and any form, award, plan or policy of the Company, the terms of this
Agreement shall govern and control. 

  
 10 

 16. SEVERABILITY. The provisions of this Agreement shall be deemed
severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. 

17. COUNTERPARTS. This Agreement may be executed in several counterparts, each of which shall be deemed to be an original
but all of which together will constitute one and the same instrument. Further, this Agreement may be executed by transfer of an originally signed document by facsimile, e-mail or other electronic means, any
of which will be as fully binding as an original document. 
 18. GOVERNING LAW; JURISDICTION. This Agreement, the rights and
obligations of the parties hereto, and any claims or disputes relating thereto, shall be governed by and construed in accordance with the laws of the State of Massachusetts without regard to its choice of law provisions. Each of the parties agrees
that any dispute between the parties shall be resolved only in the courts of the State of Georgia or the United States District Court for the District of Massachusetts and the appellate courts having jurisdiction of appeals in such courts. In that
context, and without limiting the generality of the foregoing, each of the parties hereto irrevocably and unconditionally (a) submits in any proceeding relating to this Agreement or Executive’s employment by the Company or any affiliate,
or for the recognition and enforcement of any judgment in respect thereof (a “Proceeding”), to the exclusive jurisdiction of the courts of the State of Massachusetts, the court of the United States of America for the District of
Massachusetts and appellate courts having jurisdiction of appeals from any of the foregoing, and agrees that all claims in respect of any such Proceeding shall be heard and determined in such Massachusetts State court or, to the extent permitted by
law, in such federal court, (b) consents that any such Proceeding may and shall be brought in such courts and waives any objection that Executive or the Company may now or thereafter have to the venue or jurisdiction of any such Proceeding in
any such court or that such Proceeding was brought in an inconvenient court and agrees not to plead or claim the same, (c) WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR
RELATING TO THIS AGREEMENT OR EXECUTIVE’S EMPLOYMENT BY THE COMPANY OR ANY AFFILIATE OF THE COMPANY, OR EXECUTIVE’S OR THE COMPANY’S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT, (d) agrees that service of process in
any such Proceeding may be effected by mailing a copy of such process by registered or certified mail (or any substantially similar form of mail), postage prepaid, to such party at Executive’s or the Company’s address as provided in
Section 14 hereof, and (e) agrees that nothing in this Agreement shall affect the right to effect service of process in any other manner permitted by the laws of the State of Massachusetts. 

19. MISCELLANEOUS. No provision of this Agreement may be modified, waived or discharged unless such waiver, modification
or discharge is agreed to in writing and signed by Executive and such officer or director as may be designated by the CEO. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or
provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. This Agreement together with all exhibits hereto sets forth
the entire agreement of the parties hereto in respect of the subject matter contained herein and supersedes any and all prior agreements or understandings between Executive and the Company with respect to the subject matter hereof; provided
that in the event that Executive becomes a party to any other agreement providing for restrictive covenants similar to Section 9, such agreement shall also apply pursuant to its terms. No agreements or representations, oral or otherwise,
express or implied, with respect to the subject matter hereof have been made by either party which are not expressly set forth in this Agreement. 

20. REPRESENTATIONS. Executive represents and warrants to the Company that (a) Executive has the legal right to enter into
this Agreement and to perform all of the obligations on Executive’s part to be performed hereunder in accordance with its terms, and (b) Executive is not a party to any agreement or understanding, written or oral, and is not subject to any
restriction, which, in either case, could prevent Executive from entering into this Agreement or impede Executive from performing all of Executive’s duties and obligations hereunder. 

  
 11 

 21. TAX MATTERS. 

(a) WITHHOLDING. The Company may withhold from any and all amounts payable under this Agreement or otherwise such federal, state
and local taxes as may be required to be withheld pursuant to any applicable law or regulation. 
 (b) SECTION 409A COMPLIANCE. 

(i) The intent of the parties is that payments and benefits under this Agreement comply with, or meet the requirements of an exemption under
Internal Revenue Code Section 409A and the regulations and guidance promulgated thereunder (collectively “Code Section 409A”) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted and
construed consistent with that intent. In no event whatsoever shall the Company be liable for any additional tax, interest or penalty that may be imposed on Executive by Code Section 409A or damages for failing to comply with Code
Section 409A. 
 (ii) A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement
providing for the payment of any amounts or benefits upon or following a termination of employment unless such termination is also a “separation from service” within the meaning of Code Section 409A and, for purposes of any such
provision of this Agreement, references to a “termination,” “termination of employment” or like terms shall mean “separation from service.” Notwithstanding anything to the contrary in this Agreement, if Executive is
deemed on the date of termination to be a “specified employee” within the meaning of that term under Code Section 409A(a)(2)(B), then with regard to any payment or the provision of any benefit that is considered deferred compensation
under Code Section 409A payable on account of a “separation from service,” such payment or benefit shall not be made or provided until the date which is the earlier of (A) the expiration of the six (6)-month period measured from
the date of such “separation from service” of Executive, and (B) the date of Executive’s death, to the extent required under Code Section 409A. Upon the expiration of the foregoing delay period, all payments and benefits
delayed pursuant to this Section 21(b)(ii) (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to Executive in a lump sum, and any remaining
payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. 

(iii) To the extent that reimbursements or other in-kind benefits under this Agreement constitute
“nonqualified deferred compensation” for purposes of Code Section 409A, (A) all such expenses or other reimbursements hereunder shall be made on or prior to the last day of the taxable year following the taxable year in which
such expenses were incurred by Executive, (B) any right to such reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, and (C) no such reimbursement,
expenses eligible for reimbursement, or in-kind benefits provided in any taxable year shall in any way affect the expenses eligible for reimbursement, or in-kind
benefits to be provided, in any other taxable year. 
 (iv) For purposes of Code Section 409A, Executive’s right to receive any
installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a payment period with reference to a number of days, the actual date
of payment within the specified period shall be within the sole discretion of the Company. 
 (v) Notwithstanding any other provision of
this Agreement to the contrary, in no event shall any payment under this Agreement that constitutes “nonqualified deferred compensation” for purposes of Code Section 409A be subject to offset by any other amount unless otherwise
permitted by Code Section 409A. 

  
 12 

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 13 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
written above. 
  

	
	NOVOGEN NORTH AMERICA, INC.
	
	By:                                     
                                   
	
	Name:                                     
                              
	
	Title:                                     
                                
	
	EXECUTIVE
	
	                                      
                                        

	Dr. Peng Leong

 Employment Agreement Signature Page

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]